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Abstract: More research is needed to investigate the hormonal differences and the effects 
they may have on females, with or without oral contraceptive use, in order to help increase 
our understanding of female physiology and to help create female specific guidelines for 
research and practical settings. PURPOSE: To investigate if the menstrual cycle or 
monophasic oral contraceptive (OC) use influences body temperature, mood or somatic 
symptoms and to assess menstrual cycle self-monitoring methods in at home settings. 
METHOD: 4 eumenorrheic females and 6 monophasic OC users tracked their menstrual 
cycle over 2-3 months using basal body temperature (BBT), urinary luteinising hormone 
detection kits and self-report logs. They also completed several questionnaires throughout 
each cycle. RESULTS: Non-OC users: we failed to find statistically significant differences 
across the menstrual cycle in eumenorrheic females. Analysis revealed a main effect of 
menstrual cycle phase for pain, although post-hoc analysis did not identify any specific phase 
difference. A large effect size (Cohen’s d – 0.88) was however observed for the difference 
between means of premenstrual and early follicular phases (Mean ± standard deviation (SD): 
premenstrual 9.5 ± 3.2 vs early follicular 12.7 ± 4.4; participants scored their results on a 6-
point Likert scale according to severity of experience, with higher values indicating greater 
severity). OC users: unsurprisingly, we failed to find significant differences for the majority 
of parameters measured for OC users. There was a significant difference found between 
means of behavioural change between the start and end of withdrawal week (Mean ± SD: 
start of withdrawal week 6.8 ± 2.0 vs. end of withdrawal week 6.3 ± 2.0, P = 0.001; scores 
recorded on a 6-point Likert scale according to severity of experience, with higher values 
indicating greater severity). CONCLUSION: The results indicate that body temperature, 
mood and somatic symptoms were not different across the menstrual cycle for eumenorrheic 
females. Similar results were seen in monophasic oral contraceptive users. At home 
luteinizing hormone detection kits and basal body temperature recordings were simple and 
easy to carry out at home. The BBT recordings, however, were not successful in displaying 
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I. Introduction  
Over the last few years, the number of females participating in sports has increased 
dramatically (Fink, 2015), however sports participation inequality between the two sexes 
remains (Deaner et al., 2012; van Tuyckom, Scheerder, & Bracke, 2010). The inequality is 
also seen in performance-based research (Costello, Bieuzen, & Bleakley, 2014; Mujika & 
Taipale, 2019). Between 2011 and 2013, only 39% of studies published in the journal 
Medicine and Science in Sports and Exercise included research on females. Since then, there 
has been an increase in female inclusion in research, however, it is still unequal (Bruinvels et 
al., 2017; Costello et al., 2014; Sheel, 2016). When looking at the first 5 issues of the Journal 
of Sports Physiology and Performance, published in 2019, only 19% of studies included 
females, with only 4% exclusively focusing on females. Moreover, the majority of the 
literature that explored females in sport performance has often disregarded the menstrual 
cycle and how the hormone levels may affect performance (Del Coso et al., 2013; Johnson, 
Greaves, & Repta, 2009; Lara et al., 2014), which makes it challenging to apply findings on 
this to females in sport (Emmonds, Heyward, & Jones, 2019). In addition to the above, 
tracking the menstrual cycle is vital to determine which menstrual phase the females are in 
and how it may affect sporting performance. It should be noted however that even in 
eumenorrheic females regular hormone concentration fluctuations cannot be assumed and 
therefore testing is vital to help validate the hormones (Scheid & De Souza, 2010).  
 
Hormonal contraceptive (HC) use within the athletic population is common, with 
approximately 50% of elite athletes currently using it (Martin, Sale, Cooper, & Elliott-Sale, 
2018), yet, the majority of research does not take this into account. Many studies have 
grouped naturally cycling females and oral contraceptive (OC) users in the same category, 
which is not appropriate due to the differences in hormonal profile. The lack of research and 
consideration for gender and hormonal differences between sexes leads to generalization and 
inaccurate findings. Moreover, due to the underrepresentation within the literature, male data 
is often applied to females, even though there are anatomical, physiological and 
endocrinological differences between the sexes (Heidari, Babor, De Castro, Tort, & Curno, 
2016; Pitchers & Elliot-Sale, 2019). More studies are therefore needed to investigate the 




including the menstrual cycle and/or HC (Nimphius, 2019) and help create female specific 
guidelines for research and practical settings.  
 
This project aims to determine whether the menstrual cycle or oral contraceptive use 
influence basal body temperature, mood and somatic symptoms. It also aims to determine the 
utility of self-monitoring methods. The first section of the literature review includes an 
overview of the menstrual cycle, an explanation of the hormone levels throughout the 
menstrual cycle and their effects within the body with relevance to the topic at hand. The 
thesis goes onto consider how the menstrual cycle influences muscle function and  
thermoregulation. The second section of the literature review explores the menstrual cycle 
and psychological effects, with an overview of physical and psychological symptoms 
associated with the menstrual cycle. The thesis then explores the affective and somatic 
symptoms and how they may be associated with the menstrual cycle at a greater depth. The 
eumenorrheic literature review concludes with an exploration into how the menstrual cycle 
may influence rewards and motivation. The third part of the literature review includes an 
overview of hormonal contraceptives and explores the synthetic hormones and how they may 
influence the body, including an exploration into how monophasic oral contraceptives 
influence thermoregulation. The fourth part of the literature review examines oral 
contraceptive use and psychological effects, including rewards and motivation, with a similar 
structure to section two of the literature review. Section five of the literature review reviews 
methods used for validating menstrual cycle phase, which includes an overview of self-
report, BBT and urinary luteinizing hormone (LH) measurements. The final section of the 













Impact of Coronavirus disease 19 (COVID-19) and approach taken in this thesis  
The original thesis title was ‘The acute effects of caffeine on short duration, high intensity 
performance with specific focus on the menstrual cycle phases’. Approval for this project 
was granted early in 2020 and data collection for this study and a pilot study was about to 
commence when the first national lockdown in the UK was announced (see appendix A for 
criteria and methodology). The data collection, and study, was put on pause initially, as at the 
time, we believed that the lockdown would be in place for a relatively short period of time. 
However, when it became clear that laboratory and routine data collection would not be 
possible in the near future, the project was changed to an at home-based study, which would 
allow data collection in a home setting. The change in study required considerable time to 
plan the project, recruit participants and distribute the materials to participants. Approval for 

























II. Review of literature  




The menstrual cycle is defined as the cyclical changes of the ovaries and the lining of the 
uterus which repeats monthly, beginning at puberty and ending at menopause (Thiyagarajan 
& Jeanmonod, 2019). The menstrual cycle is regulated by changes in specific hormones; the 
gonadotrophin-releasing hormones, follicle-stimulating hormone (FSH) and LH, and the sex 
steroid hormones (oestrogen and progesterone) (Boivin & Shechter, 2010; Messinis, Messini, 
& Dafopoulos, 2014) (figure 1). The cycle can be divided into two distinct main phases, the 
follicular phase and the luteal phase, which can be further spilt into subphases.  The 
subphases help highlight any changes that may occur due to the hormonal fluctuations in 
each main phase.  
 
 
Figure 1 Estradiol and progesterone over a typical '28 day' menstrual cycle 
 
 
The follicular phase begins from the first day of menstrual bleeding until ovulation (~ 12 - 14 
days in a ‘typical’ cycle) (Bull et al., 2019). The early follicular phase consists of low 



















































to rise, due to FSH stimulating growth and development of ovarian follicles, and 
progesterone levels remain low (De Jonge, Thompson, & Han, 2019). The increase in 
oestrogen levels cause a surge in LH, released from the pituitary gland, which initiates 
ovulation. It should be noted that individuals may not ovulate every menstrual cycle (Fairley 
& Taylor, 2003), if ovulation does not occur the cycle is termed an anovulatory cycle. The 
luteal phase starts after ovulation and continues to the onset of menses; this phase consists of 
high oestrogen and progesterone levels (figure 1). It is worth mentioning, however, that 
oestrogen levels are not as high in the luteal phase as they are in the preovulatory phase.  
 
The length of the menstrual cycle is the number of days from the first day of menstrual 
bleeding of one cycle to the day before the subsequent bleeding onset of the next cycle. A 
typical menstrual cycle lasts 28 – 30 days (Bull et al., 2019; Faust et al., 2019; Harlow, Lin, 
& Ho, 2000; Rosner & Sarao, 2019). In a typical cycle, the luteal phase is relatively 
consistent between women (~14 days) (Reed & Carr, 2000), whereas there is greater inter 
individual variance in the follicular phase, which usually vary between 10 - 16 days (Bull et 
al., 2019; Cole, Ladner, & Byrn, 2009; Faust et al., 2019; Fehring, Schneider, & Raviele, 
2006; Frankovich & Lebrun, 2000; Mihm, Gangooly, & Muttukrishna, 2011; Mumford et al., 
2012; Sherman & Korenman, 1975). Females who experience a typical menstrual cycle 
length are termed eumenorrheic. Females who experience menstrual cycle lengths less than 
21 days are termed polymenorrhagia, and individuals who experience longer menstrual 
cycles (> 35 days) are termed oligomenorrheic.  
 
Key hormones: oestrogen & progesterone  
 
Oestrogen and progesterone are steroid hormones, secreted primarily from the ovaries. 
Oestrogen binds to oestrogen receptors (ER), including oestrogen receptor alpha (ERα) and 
oestrogen receptor beta (ERβ) (Hansen, 2018; Ikeda, Horie-Inoue, & Inoue, 2019; Lee, Kim, 
& Choi, 2012). Progesterone binds to two receptor proteins: progesterone receptor alpha 
(PRα) and progesterone receptor beta (PRβ) (Brinton et al., 2008; Spelsberg, Steggles, Chytil, 
& O’Malley, 1972). Although the primary role of both hormones is to support reproduction, 





Muscle function  
 
Several studies have demonstrated that menopause-related strength loss is connected to a 
decrease in oestrogen concentration, suggesting that oestrogen plays a role in muscle function 
(Samson et al., 2000). Skeletal muscle is the largest tissue containing oestrogen receptors 
(Wiik, Ekman, Johansson, Jansson, & Esbjörnsson, 2009), further suggesting that there may 
be a connection between the hormone and skeletal muscle. Collins et al. (2018) studied ERα 
deletion in mice and found that skeletal muscle contractility was impaired. Similar results 
were concluded by Cabelka et al.  (2019) which helps signify that ERα is necessary for 
optimal muscle force production (Collins, Laakkonen, & Lowe, 2019; Lowe, Baltgalvis, & 
Greising, 2010). Moreover, oestrogen may also affect myofiber growth and regeneration. 
Kitajima and Ono (2016) studied mice with oestrogen reduction compared to mice with 
sufficient oestrogen. Mice with insufficient oestrogen had significantly compromised muscle 
regeneration compared to mice with sufficient oestrogen. The mice with insufficient 
oestrogen also had impaired satellite cell expansion, differentiation and self-renewal. The 
study highlighted that oestrogen was essential for maintaining muscle function, including 
muscle recovery. Similar findings are suggested by McClung, Davis, Wilson, Goldsmith, and 
Carson (2006) and Diel (2014). It would therefore be probable to expect that when oestrogen 
levels are high, muscle recovery and/or strength may be increased. Bambaeichi, Reilly, 
Cable, and Giacomoni (2009) studied sedentary females across 5 phases: 1-4 days from first 
day of menstrual bleeding, days 7-9 (mid-follicular), around ovulation (confirmed by urine 
LH spike), days 19-21 (mid-luteal) and days 25-27 (late luteal). They found significantly 
higher values for maximal voluntary isometric contraction (MVIC) of knee flexors around 
ovulation (62.7 N.m), when oestrogen levels are at their highest, compared to the mid-
follicular phase (58.7 N.m) and mid-luteal phase (56.4 N.m). There was however no 
significant change in MVIC of knee extensors. Additionally, the study demonstrated 
differences in peak torque of knee flexors and extensors across the menstrual cycle, with an 
increase in peak torque after ovulation. Tenan, Hackney and Griffin (2016) investigated five 
phases. They found that maximal voluntary contraction (MVC) of the knee extensors 
decreased by 23% from ovulation to the mid luteal phase, but when individuals reached the 
late luteal phase, MVC returned to values similar to the other phases. This could be due to 
progesterone reaching its peak and therefore potentially having a negative effect on strength 
production. De Jonge, Boot, Thom, Ruell, and Thompson (2001) however, studied 19 healthy 




contractile properties of each participant in three phases: the early and late follicular phases 
and the luteal phase. The study concluded that there was no change over the menstrual cycle 
for any parameters studied. Similar results were concluded by Fridén, Hirschberg, & Saartok 
(2003). Montgomery & Shultz (2010) investigated recreationally active individuals. For a 2-
month period prior to testing, individual’s serum was obtained for 6 days after onset of 
menstrual bleeding (early follicular phase) and for 8 days after a positive LH test (luteal 
phase). The researchers investigated and tracked the individuals’ estradiol, progesterone and 
testosterone concentrations in order predict and set dates for testing. Individuals were tested 
during the early follicular phase and luteal phase. During MVIC testing, serum hormone 
levels were also obtained. The study found no changes in MVIC of the knee flexors and 
extensors between the two phases. The discrepancies between the studies could be due to 
methodological factors (Pereira, Larson, & Bemben, 2020). For example, the number of 
experimental trials over the menstrual cycle; many of the studies only tested two – three 
phases within the menstrual cycle, whereas Bambaeichi et al. (2004) and Tenan et al. (2016) 
tested in five phases. Moreover, several of the studies did not test around ovulation when 
hormonal levels may have played a role. Another limitation, and potential cause for 
discrepancies, could be the lack of consistency in methods used to track the menstrual cycle. 
Sims and Heather (2018) recently proposed that investigations should include a three-step 
method to track the menstrual cycle: collection and evaluation of serum hormone 
concentrations, cycle mapping and urinary ovulation prediction.  
 
Furthermore, when investigating increased muscle recovery, the literature is equivocal. 
Hackney, Kallman, and Aǧgön (2019) investigated muscle damage during recovery of trained 
individuals during two phases in the menstrual cycle (mid-follicular and mid-luteal). After 
running on a treadmill for 90 minutes at 70% maximum rate of oxygen consumption 
(VO2max), creatine kinase (CK) activity and interleukin-6 (IL-6) concentration was greater in 
the mid-follicular phase than mid-luteal phase at both 24 and 72 hours into recovery. 
Moreover, IL-6 was significantly greater in the mid-follicular phase compared to the mid-
luteal phase, immediately post exercise and at 24 hours and 72 hours into recovery. The 
results suggest that during the mid-follicular phase, when oestrogen and progesterone are 
low, muscle recovery takes longer after endurance performance. In contrast, when 
investigating recovery in strength/resistance training, Markofski & Braun, (2014) found that 
recovery post exercise was better in the follicular group (when hormones are low). The study 




proposed that oestrogen concentration during the recovery week could be more beneficial 
compared to oestrogen concentration at the time of muscle damage. In other words, the phase 
(and hence hormone levels) during the first few day’s post-exercise may be more important, 
and this may not necessarily be the same phase in which the exercise took place (for example, 
if this occurred near to the transition into the next phase). Another suggestion could be that 
there was insufficient oestrogen to aid recovery. Refer to section ‘rewards and motivation’ 
for more information on how muscle function/recovery may influence an individual’s 
perceptions on how they feel about exercise throughout the menstrual cycle, in regards the 
motivation/readiness to train.  
 
 Thermoregulation  
 
It has been suggested that both oestrogen and progesterone influence thermoregulation 
through their influence on the hypothalamus (Baker, Waner, et al., 2001; Morrison & 
Nakamura, 2019). In a typical menstrual cycle (figure 2), a biphasic curve can be seen in 
basal body temperature (BBT) (temperature at rest) with lower temperature in the follicular 
phase (<36.5 °C) and sustained, higher temperatures in the luteal phase (~36.7 °C); the 
difference has been shown to be ~ 0.3 - 0.5 °C between the two phases) (Baker, Mitchell, & 
Driver, 2001; Baker, Waner, et al., 2001; Cagnacci, Arangino, Tuveri, Paoletti, & Volpe, 
2002; Marshall, 1963; Stephenson & Kolka, 1999; Vidafar et al., 2018). Moreover, ~1 day 
prior to the LH surge, BBT reaches its lowest point before increasing into the early luteal 
phase (Coyne, Kesick, Doherty, Kolka, & Stephenson, 2000; Stephenson & Kolka, 1999). As 
progesterone levels drops in the late luteal phase, BBT returns to the lower range ~ 1 - 2 days 
before the onset of menstrual bleeding (de Mouzon, Testart, Lefevre, Pouly, & Frydman, 
1984; Su, Yi, Wei, Chang, & Cheng, 2017). The BBT and the biphasic curve can be used to 
retrospectively detect ovulatory cycles and thus predict phases of the menstrual cycle (Bull et 
al., 2019; Kawamori, Fukaya, Kitazawa, & Ishiguro, 2019; Tenan et al., 2016; Tenan, Peng, 
Hackney, & Griffin, 2013).  
 
It is suggested that progesterone is responsible for the hyperthermic effect seen in the luteal 
phase (Isreal & Schneller, 1950; Stachenfeld, Silva, & Keefe, 2000), as it occurs alongside 
the progesterone peak. Whereas, oestrogen is responsible for a hypothermic effect, 
highlighted when oestrogen levels increase and temperature reaches its lowest point (Coyne 




through the enhancement of  vasodilation for heat loss and sweat (Brooks et al., 1997; 
Charkoudian, Stephens, Pirkle, Kosiba, & Johnson, 1999).   
 
Moreover, Cagnacci et al. (2002) investigated the progesterone/estradiol ratio and found that 
it was the best predictor variable of body temperature changes throughout the menstrual cycle 
when compared to investigating progesterone and/or oestradiol separately. Grant et al. (2020) 
investigated the effects of progesterone and the progesterone/estradiol ratio on core body 
temperature between the follicular and luteal phases. They found that progesterone and the 
progesterone/estradiol ratio were significantly associated with core body temperature (P=0.02 
and 0.01, respectively). Other researchers have however, disputed progesterone’s 
hyperthermic effect due to the poor correlation between BBT and progesterone concentration 
(Forman, Chapman, & Steptoe, 1987; Kesner, Wright, Schrader, Chin, & Krieg, 1992; 
Morris, Underwood, & Easterling, 1976). Additionally, if researchers have not measured 
hormonal concentrations alongside BBT, it therefore cannot be assumed that the hormone 
concentrations vary in relation to the BBT values. BBT can also be influenced by lifestyle 
factors such as stress, alcohol consumption, sleep, diet, nutritional factors, medications and 
illness (Barron & Fehring, 2005). There are many ways to measure and interpret BBT: 
specialized charts, online services or smart-phone applications, with some of the 
interpretations not being clear. BBT is however an easy, non-invasive tool to measure the 
menstrual cycle but interpretation might be challenging, and it would be best to combine this 
methodology with another form of testing to validate results (Barron & Fehring, 2005; 
Bauman, 1981; Bouchard & Genuis, 2011).   
 



























Throughout the menstrual cycle, women can experience changes in their physical and 
psychological symptoms (Romans, Clarkson, Einstein, Petrovic, & Stewart, 2012). Oestrogen 
and progesterone have receptors localised in the amygdala, hippocampus, cortex and basal 
forebrain; regions of the brain involved in emotional and cognitive regulation (Wharton, 
Gleason, Sandra, Carlsson, & Asthana, 2012). The sex hormones have been observed to 
modulate the synthesis, release and metabolism of several neurotransmitters including 
serotonin, dopamine, noradrenaline and melatonin. The hormones have also been observed to 
modulate synaptic functions. Serotonin, a neurotransmitter, has a variety of roles within the 
body, including regulating the body’s sleep wake cycle and an individual’s wellbeing and 
happiness; higher levels of serotonin are associated with increased feelings of wellbeing and 
happiness (Rybaczyk et al., 2005). Oestrogen and progesterone have been seen to play a role 
in serotonergic function (Barth, Villringer, & Sacher, 2015). Oestrogen has been observed to 
upregulate serotonin synthesizing enzyme (tryptophan hydroxylase messenger ribonucleic 
acid [mRNA]), and downregulate serotonin reuptake transporter mRNA, which suggests that 
oestrogen can influence serotonin availability and concentration within the central nervous 
system Aggarwal, Puri, & Puri, 2012). This can be seen through the use of serotonin reuptake 
inhibitors for reduction of premenstrual syndrome (PMS) symptoms (Shah et al., 2008). 
Moreover, high oestrogen levels have been shown to reduce anxious behaviour (Walf & Frye, 
2007). On the other hand, progesterone has been observed to increase serotonin turnover, 
reducing serotonin concentration and availability, which might be related to increased 
depressive symptoms (Barton et al., 2008), anxiety and irritability (Andréen, Bixo, Nyberg, 
Sundström-Poromaa, & Bäckström, 2003; MacQueen & Chokka, 2004; Saunders & Hawton, 
2006) 
 
 Affective and somatic symptoms  
 
Mood changes have been found to occur in both menstrual phases (follicular and luteal) 
(Boyle & Grant, 1992; Brahmbhatt, Sattigeri, Shah, Kumar, & Parikh, 2013; Van Den Akker 
& Steptoe, 1985). Psychological changes associated with the menstrual cycle have been 





PMS is defined as the ‘reoccurrence of negative behavioural, psychological and physical 
symptoms’ that occur during the luteal phase of the menstrual cycle (Dickerson, Mazyck, & 
Hunter, 2003; Farage, Osborn, & MacLean, 2008; Freeman, 2003; Gnanasambanthan & 
Datta, 2019; Kessel, 2000; Ryu & Kim, 2015). PMS symptoms are sometimes severe enough 
to interfere with an individual’s daily activities. Brahmbhatt et al. (2013) found that 80% of 
women reported mild symptoms with 20-50% reporting moderate and ~5% reporting severe, 
similar findings have been found by Moos (1968). PMS symptoms are common within the 
general population (Brahmbhatt et al., 2013) and elite athlete population (Findlay, MacRae, 
Whyte, Easton, & Forrest, 2020), and tend to worsen 6 days prior (mid-late luteal phase) and 
peak ~2 days prior to the onset of menses (Kimberly Ann Yonkers, O’brien, & Eriksson, 
2008), with symptoms subsiding into the early follicular phase (Ross, Coleman, & 
Stojanovska, 2003). Cohen, Sherwin, & Fleming (1987) found that moods were less positive 
in the luteal phase compared to the follicular phase, with the lowest moods evident on 
premenstrual days. Symptoms of PMS / menstrual cycle symptoms can include mood and 
behavioural symptoms (affective symptoms) and somatic symptoms, including but not 
limited to breast tenderness, bloating, muscle pain, fatigue, and low energy (see table 1). The 
way in which the symptoms originate is still unclear, however, it is believed that the 
fluctuations in the sex hormones, oestrogen and progesterone, play a role.  
 
Ross et al. (2003) investigated the patterns of the menstrual cycle in 181 women, either with 
or without HC use. Each participant completed a modified menstrual distress questionnaire 
(MDQ) every evening daily for 70 days. The authors standardised each menstrual cycle into a 
28-day record, by a mathematical interpolation, and scores were derived by averaging the 
symptom scores as followed for each phase: follicular days 7 – 11, late luteal days 24 – 28 
and menstrual period days 2 – 4. In women without HC use, the authors demonstrated that 
symptoms were at their lowest during the follicular phase and increased in the premenstrual 
phase. Somatic symptoms, which include backache, cramps and general aches and pains, 
were significantly higher during the menstrual phase compared to the premenstrual phase 
whereas fluid retention was significantly higher in the premenstrual phase compared to the 
menstrual phase. Similar results were reported by Heitkemper & Jarrett (1992). The study 
investigated a variety of parameters including mood symptoms, somatic symptoms and 
perimenstrual symptoms across two menstrual cycles. They separated the phases as followed: 




10, -9 & -8 prior to onset of next menses). They found that MDQ-T scores were higher for 7 
out of 8 subscales (arousal was lower) at menses compared to the follicular and luteal phase. 
Further analysis showed that menses scores were higher for all but the control and arousal 
subscales compared to the follicular. Moreover, menses scores were significantly higher than 
the luteal phase for pain, behaviour change, impaired concentration and autonomic reactions. 
Lu (2001) assessed individuals using a prospective diary (Woods daily health diary) and 
using a retrospective questionnaire (MDQ) over a 90 day period (or 3 menstrual cycles). The 
Woods daily health diary was split into three phases: premenstrual (7 days prior to onset of 
menses), menstrual (all bleeding days) and postmenstrual (all remaining days of cycle). The 
MDQ captured three cycle phases: 4 days prior to menses, days of the most recent menses 
and the remainder of the cycle. Upon analysis of the daily diary, Lu (2001) found that mean 
values for abdominal pain, cramps and general aches and pains were significantly higher 
during the menstrual phase compared to the pre and post menstrual phase, whereas symptoms 
of hostility were significantly higher during the premenstrual and menstrual phase compared 
to the post menstrual phase. The retrospective MDQ highlighted that over 60% of women 
reported suffering from physical, psychological and behavioural changes (i.e., fatigue, 
cramps, mood swings and taking naps) during the menstrual cycle and  over 60% reported 
suffering from painful or tender breast and fatigue during the premenstrual phase. Moreover, 
it was noted that fatigue was the most frequent and severe symptoms during the premenstrual 
and menstrual phase with cramps and abdominal pain the second most frequent symptom 
during the menstrual phase. It is also important to highlight that 3.3% of women reported 
symptoms that included loneliness, fatigue and avoidance of social activity during the 
menstrual phase. Li, Lloyd, & Graham (2020) however found that physical fatigue, assessed 
through a fatigue and energy scale, remained unchanged between the early follicular phase 
(days 10 – 14 prior to ovulation) and the mid luteal phase (days 5 – 10 after ovulation) 
whereas mental fatigue significantly increased from the early follicular to mid-luteal phase in 
non-anxious women. Mental fatigue remained unchanged in women in generalised anxiety 
disorder, which may suggest that hormonal levels differ in women with and without 
generalised anxiety disorder, which may indirectly or directly influence fatigue.  
 
Similarly, Gonda et al. (2008) found that during the late luteal phase (2-3 preceding the onset 
of menses) scores were significantly higher in anxiety and depression when compared to the 
early and late follicular phase. Similar results are echoed by Abraham, Luscombe, & Soo 




were asked to record their mood changes throughout one menstrual cycle. The individuals 
collected morning salvia samples at home, which were analysed for progesterone 
concentration. The study found that over 80% of the females reported negative mood 
symptoms during the luteal phase, with 75% reporting an increase in aggressive, irritable, and 
depressive behaviour during this phase. When looking at the saliva analysis, the study 
reported that women who reported lower intensities for aggressive or irritable behaviour had 
significantly higher levels of progesterone throughout the entire luteal phase when compared 
to women who reported higher intensities of aggressive/irritable behaviour. 
Aggressive/irritable behaviour was defined as the ‘sum of intensity of symptoms such as 
anger and irritability’. However, the study did not find any statistically significant differences 
in progesterone levels between women who had high and low intensity depressive behaviour. 
When progesterone levels are high in the luteal phase, Conway et al. (2007) found that 
individuals had a greater tendency to perceive fearful expressions as more intense (Toffoletto, 
Lanzenberger, Gingnell, Sundström-Poromaa, & Comasco, 2014). Similar results were found 
by Andreano and Cahill, (2010) who studied 17 naturally cycling females. The study 
conducted testing during two phases of the menstrual cycle (early follicular phase and mid-
luteal phase). During functional magnetic resonance imaging (fMRI) scans, focusing on the 
amygdala responsiveness, the individuals were exposed to negative emotional and neutral 
images. The study found that during the mid-luteal phase, response to negative emotional and 
neutral images were significantly greater than during the follicular phase. Similar 
observations were found by Freemas et al. (2020), suggesting and reinforcing that the 
hormonal balance plays a role in the individuals’ emotions.  
 
A few studies, however, have found that women who suffer from higher anxiety reported 
more severe symptoms regardless on the menstrual cycle phase (Craner, Sigmon, & Young, 
2016; Nillni, Rohan, Mahon, Pineles, & Zvolensky, 2013; Sigmon, Dorhofer, Rohan, & 
Boulard, 2000). Additionally, in a review of prospective data studies surrounding the mood 
and the menstrual cycle, Romans, Clarkson, Einstein, Petrovic, and Stewart (2012) suggests 
that many studies contain misinformation. The aforementioned study suggests that 
menstruation may have negative connotations and therefore influence individuals’ attitudes, 
mood, emotions and physical pain. For example, there have been a few studies which have 
investigated females’ expectations of PMS / menstrual cycle symptoms. Marván and 
Escobedo (1999) had two groups of females: 1 group watched a negative video of PMS, and 




negative video reported increased PMS symptoms compared to the control group. Similar 
findings have been suggested by Ruble (1977). It is therefore important to take into account 
individuals, their attitudes, beliefs and baseline measurements, when comparing data 
(Marván, Vázquez-Toboada, & Chrisler, 2014).  
 
Table 1. Menstrual cycle symptoms 
 
Rewards & motivation  
Motivation is defined as “direction and intensity of effort” typically in an effort for a reward 
(Weinberg & Gould, 2007). Dopamine is a catecholamine neurotransmitter (Fernstrom & 
Fernstrom, 2007), with dopaminergic neurons located in the substantia nigra and extending to 
the dorsal striatum, making up the dopaminergic pathways. Dopamine receptors are 
expressed in the central nervous system (CNS) and also found peripherally in blood vessels, 
kidneys, heart, retina and adrenals which control catecholamine release. Dopamine plays a 
role in our behaviour and physical function such as motivation and learning (Hikosaka, 
Nakamura, Sakai, & Nakahara, 2002; Salamone & Correa, 2012; Westbrook & Braver, 
2016), sleep (Monti & Monti, 2007; Wisor et al., 2001), mood movement/locomotor activity 
(Harrington, Augood, Kingsbury, Foster, & Emson, 1996), endocrine regulation and food 
intake. As mentioned previously, steroid sex hormones, oestrogen and progesterone, have 
been observed to interact with dopamine. Oestrogen has been seen to increase an individual’s 
reactions to reward stimuli by increasing synthesis and release of dopamine (Sakaki & 
Mather, 2012). However, when progesterone levels are high, oestrogen receptors are 
downregulated. Therefore, it is plausible to assume that during the follicular phase compared 
to the luteal phase, an individual’s reaction and effort to reward is a lot stronger (Justice & 
De Wit, 2000; White, Justice, & De Wit, 2002; Yoest, Cummings, & Becker, 2015).  
 
Affective symptoms Somatic symptoms 
Anger Headache 
Anxiety Tender/swollen/painful breasts  
Social withdrawal Water retention  
Confusion  Abdominal bloating 
Depression Joint or muscle pain  
Irritability  Low energy / fatigue 




Moreover, testosterone, a sex hormone, is involved in voluntary motivation. Testosterone 
levels increase prior to ovulation and prior to onset of menses. Cook and Beaven (2013) 
demonstrated that increased levels of testosterone were linked with increased motivation to 
train. Similar results were concluded by Cook, Kilduff, and Crewther (2018) who showed 
that females had a higher motivation to train on day 14 (near ovulation) compared to the mid-
follicular and mid-luteal phase. Furthermore, a review completed by Yesildere Saglam and 
Orsal (2020) demonstrated the effect of exercise on PMS with many studies showing positive 
influences on improving physical and psychological symptoms. However, PMS / menstrual 
cycle symptoms like fatigue, tiredness and decreased mood can affect motivation to complete 
exercise in the days leading up to the follicular phase (Lustyk & Gerrish, 2010; Takeda, 
Imoto, Nagasawa, Muroya, & Shiina, 2015). 
 
The hormonal fluctuations seen throughout the menstrual cycle could contribute to the 
individuals self-reported perceptions of how they feel about training or exercising, in relation 
to their readiness/motivation to train. Armour, Parry, Steel, and Smith, (2020) found that 
athletes experienced perceived reductions in performance, with increased fatigue and reduced 
strength, speed and agility during or just prior to the onset of menses. Moreover, Brown, 
Knight, and Forrest (2020) found that athletes often felt ‘sluggish during training’ due to 
feeling lethargic, pre and/or during their menses. Interestingly, the authors noted that a large 
proportion of participants often lacked the motivation to train as they would rather do more 
passive activities, which required less energy, or nothing at all. Lack of motivation to train 
was often down to having no energy or physical symptoms such as pain/bloating impacting 
performance. The individuals preference for low intensity and/or low energy requiring 
exercise or none at all may be due to the additional perceived effort that is needed to carry 
out exercise pre/during menses. Hooper, Bryan, and  Eaton (2011) discovered that during the 
early follicular / menses phase, females had significantly greater increases in ratings of 










HC’s suppress the normal menstrual cycle hormones, via negative feedback, by inhibiting 
hypothalamic release of gonadotrophin-releasing hormones (Elliott-Sale et al., 2013), which 
results in the downregulation of endogenous oestrogen and progesterone (Elliott, Cable, & 
Reilly, 2005), decreased production of testosterone (Zimmerman, Eijkemans, Coelingh 
Bennink, Blankenstein, & Fauser, 2014) and inhibition of ovulation. There is a variety of HC, 
including the combined oral OC, which contains synthetic exogenous oestrogen (ethinyl 
estradiol (EE) at 15 – 35 µg) and progestin (Hampson, 2020) and a progestin-only 
contraceptive. Combined OCs are the most commonly used within the athletic population 
(Martin et al., 2018; Rechichi, Dawson, & Goodman, 2009). There are three types of 
combined OCs: monophasic, biphasic and triphasic. The monophasic OC have a constant 
dose of exogenous oestrogen and progestin over 21 days (OC consumption phase), with a 7-
day period involving no pill or a placebo pill (OC withdrawal phase) (see figure 3). 
Monophasic exogenous hormone half-lives should be noted, as it takes 7 days of pill 
consumption to completely downregulate the pituitary glands and 5 days of OC withdrawal to 
stabilise progestin levels (Elliott et al., 2005). Creinin, Lippman, Eder, Godwin, and Olson 
(2002) suggested that the withdrawal phase should be termed a transient hormonal profile 
phase due to this. The biphasic and triphasic OC hormone doses may vary throughout the 
cycle. The ‘controlled’ menstrual cycle lasts 28 days (Redman & Weatherby, 2004), with a 
withdrawal bleed (artificial period) occurring during the pill withdrawal phase. There are 
several brands of combined OCs, each containing different doses of the two synthetic 
hormones and different potencies of progestin (Burrows & Peters, 2007; Christin-Maitre, 






Figure 3. Exogenous and endogenous hormones throughout the menstrual cycle for females using monophasic 
oral contraceptives. 
 
Key hormones: oestrogen & progestin 
 
As mentioned previously, OCs contain two synthetic exogenous hormones: the oestrogen 
component is estradiol and progesterone component is progestin. Since OCs were first 
released, the OC generations have changed formulations. The OC generation relies on the 
type of progestin used; the newer generations (second and third) contain different doses of 
both hormones and the progestin has lower androgenic properties to reduce / decrease 
potential side effects such as acne and oily skin. As OCs downregulate endogenous 
hormones, inhibit ovulation occurring and help stabilise the hormonal levels, it is 
hypothesized that the physical, psychological, and emotional symptoms that are associated 
with hormonal fluctuations do not occur or are reduced. 
 
Thermoregulation  
As mentioned in the thermoregulation section of non-OC users, the steroid hormones, 
oestrogen and progesterone, have been seen to play a role in thermoregulation, with increases 
in BBT during luteal phase of the menstrual cycle.  Several studies have investigated whether 
the synthetic steroids in OC influence thermoregulation in a similar manner. Baker, Mitchell, 
and Driver (2001) investigated 11 monophasic OC users and 12 non-OC users. Endogenous 
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and, as expected, were significantly lower than naturally cycling women in both phases. The 
study found that during a 24 hour recording period, OC users had a similar mean temperature 
across both phases (pill and withdrawal, 37.4°C), with temperatures similar to those of non-
oc users in the luteal phase (37.4°C). Similarly, Baker et al. (2001) discovered that during a 
24 hour recording period, monophasic OC users during the pill consumption phase had 
similar endogenous hormone concentrations to those of non-oc users in the follicular phase 
(both hormones low). Moreover, temperatures during the pill consumption phase were similar 
to those of non-oc users during the luteal phase (37.5°C and 37.4°C, respectively). It is 
therefore reasonable to assume that OC users do not follow the same temperature pattern 
compared to non-oc users. There are a few mechanisms of action which may be responsible 
for this. Rogers and Baker (1996) suggested that the increase in temperature throughout both 
phases (pill consumption and withdrawal) may be due to the synthetic hormones increasing 
the body’s core temperature. In contrast, Lei et al. (2019) compared days 3-5 and days 18-20 
following start of monophasic OC consumption. Their findings demonstrated that rectal 
temperature was significantly higher during days 18-20 compared to days 3-5 (0.15°C 
difference), alongside this, both endogenous and exogenous hormone concentrations of 
oestrogen and progesterone did not differ between the two time points, suggesting that 
neither endogenous nor exogenous played a role in the temperature increase. Although, it 
should be highlighted that the temperatures were recorded at rest and not measured as BBT 
measurements (i.e., in the morning upon waking).  
 
It should be noted that it can take up to 5 days of OC withdrawal to stabilise progestin levels 
and therefore the standardisation of ‘at least 3 days’ after pill withdrawal could lead to 
inaccurate findings in Baker, Mitchell, et al. (2001) investigation. It is of interest to also point 
out that studies like the one mentioned and Baker, Waner, et al. (2001) did not standardise the 
day(s) within the consumption phase when recordings were carried out, which again, may 
influence results collected. 
 
Stachenfeld et al. (2000) investigated the effects of combined oestrogen and progestin and of 
progestin only oral contraceptives on nine healthy women. Individuals’ baseline 
measurements were assessed in the early follicular phase and midluteal phase, without OC 
consumption. Each treatment group lasted four weeks, with a four week washout period 
before subjects crossed over to the other treatment. Body core temperature was measured 




administered, there was an increase in core temperature and threshold for sweating, however, 
when oestrogen was administered with progestin, the effects were reversed. It should, 
however, be highlighted that oestrogen’s hypothermic effect may only be temporary, as 
progesterone’s hyperthermic effect is dominant (Isreal & Schneller, 1950). It should be noted 
that four weeks of OC consumption may not be long enough to allow the body to adjust to 
the exogenous hormones. The mechanisms of action are still unclear; however, it is likely 
that the steroids influence the hypothalamus in a similar manner to the endogenous sex 
hormones.  
 
Oral contraceptive use and psychological effects  
Overview  
 
It is thought that the downregulation of endogenous hormones may stabilise and possibly 
reduce the effects the menstrual cycle has on the body. There is however no consensus within 
the literature, with some studies suggesting that OCs may have a negative effect (Robinson, 
Dowell, Pedulla, & McCauley, 2004), no effect (Bruni et al., 2000; Marriott & Faragher, 
1986) or a positive effect (Boyle & Grant, 1992) on affective and/or somatic symptoms 
(Graham, Bancroft, Doll, Greco, & Tanner, 2007; McKetta & Keyes, 2019; Robakis, 
Williams, Nutkiewicz, & Rasgon, 2019). The lack of consensus may be due to the variety of 
OCs, the dose of oestrogen and progestin and progestins potency (as discussed previously) as 
well as methodological differences used within the literature (Oinonen & Mazmanian, 2001; 
Schaffir, Worly, & Gur, 2016).  
 
Affective and somatic symptoms  
 
HC’s have been thought to help reduce levels of depressive symptoms (Keyes et al., 2013). 
Joffe et al. (2007) found that females taking monophasic OCs (30 µg EE and 3mg 
drospireone) alongside their antidepressant medication significantly helped treat premenstrual 
depression, which is seen in the luteal phase of the cycle. Toffol, Heikinheimo, Koponen, 
Luoto, and Partonen (2011) studied OCs, their results highlighted lower but not significant 
scores of the beck depression inventory for OC users compared to non-OC users, suggesting 
that OCs did not have detrimental effects on mood. Similar findings were suggested by 
Toffol, Heikinheimo, Koponen, Luoto, and Partonen (2012) and McKetta and Keyes (2019). 




effect of the OC on menstrual cycle mood and symptoms, 65% of OC users felt as though 
their psychological moods were reduced by the OC use, although it should be noted that the 
OC type/brand was not disclosed. Similarly, the results could be due to a placebo effect, i.e., 
participants believe that using OC’s will reduce their symptoms compared to testing with and 
without OC. Interestingly, the study completed further analysis on the menstrual attitude 
questionnaire and found that the non-oc users did report menstruation as significantly more 
debilitating than the oc users, although none of the other items measured showed any 
significant difference. When analysing the MDQ, oc users did report significantly fewer 
symptoms and negative moods than non-oc users. The findings may be due to the OC 
stabilising the hormonal levels through the more ‘controlled’ and ‘steady’ exogenous 
hormones throughout the cycle and therefore ‘protecting’ the individual from their 
endogenous hormones and what effect they may have on mood. This can be seen through 
Abraham, Luscombe, and Soo (2003) study whereby non-OC individuals had a sharp 
premenstrual increase in sadness/depression frequency compared to OC-users (Natale & 
Albertazzi, 2006).  Alternatively, it has been suggested that OC users experience negative 
psychological side effects due to the exogenous hormones. Zethraeus et al. (2017) 
investigated individuals taking a monophasic OC for three months (30 µg EE & 150 µg 
levonorgestrel and) and found that individuals who used the OC compared to non-oc users 
had a significant reduction (6%) in general well-being from baseline to 3 months post OC 
consumption. However, it should be noted that there was no significant difference in negative 
mood/depressive symptoms in OC users compared to non-OC users in the study. A possible 
mechanism of action could be that exogenous progestin having a similar effect to endogenous 
progesterone; exogenous progestin has been observed to reduce serotonin concentration and 
availability, which therefore negatively affect an individual’s mood (Holst, Bäckström, 
Hammarbäck, & von Schoultz, 1989; Klaiber, Broverman, Vogel, Peterson, & Snyder, 1996). 
This theory is reinforced through the increased risk of depression in progestin only pills 
(Skovlund, Mørch, Kessing, & Lidegaard, 2016; K. Smith et al., 2018). Furthermore, the 
differences in findings could be due to the individuals investigated. Garbers, Correa, Tobier, 
Blust, and Chiasson (2010) highlighted that individuals who have higher depressive 
symptoms or are screened positive for depression are less likely to use exogenous 
contraception methods, including OCs and therefore if  individual’s with lower levels of 
depression are investigated in the studies, it is likely that their depression scores will be lower 





Mood lability (changes in mood) has also been investigated. Ott, Shew, Ofner, Tu, and 
Fortenberry (2008) demonstrated that OCs, when compared to depot medroxyprogesterone 
acetate (a HC), helped reduce variation in mood. Similar results were concluded by Taggart, 
Eaton, Keyes, Hammett, and Ulloa (2018) who compared OC users and Non-OC users. Their 
study found that OC users reported a 41 % presence of mood lability compared to non-OC 
users reporting 63 %. Although, it should be noted that the study did not report what 
type/brand of OCs were studied. Graham, Bancroft, Doll, Greco, and Tanner (2007) studied 
individuals pre- and post-3 months of taking a triphasic OC. The results concluded that there 
was no significant change in mood due to the triphasic OC. Upon closer inspection of the 
data however, large groups can be seen in each of the following categories: no change (19), 
positive (17) and negative change (24). The results highlight the variety of individual 
responses, which may suggest it is up to the individuals as to how they respond to OC use 
(Oinonen & Mazmanian, 2002; Robakis et al., 2019). Moreover, the equivocal findings could 
also be due to the use of different generations of OCs within the studies. Shahnazi et al. 
(2014) studied second and third generation OC’s and their effect on mood. The study 
concluded that third generation OCS are better for mood stability than second generation due 
to the lower potency of progestin. It is therefore challenging to draw conclusions between 
studies when a variety of OC generations with various progestin levels have been used and/or 
the OC generations/types have not been disclosed.  
 
Nyberg (2013) investigated women who suffered with or without PMS symptoms. All 
subjects were placed on monophasic OC (35 µg EE / 250 µg norgestimate). The study found 
that females who suffered with severe PMS showed improved mood symptoms although 
females who showed no or mild PMS symptoms did not show any significant improvement 
or decline in symptoms. Sanders, Graham, Bass, and Bancroft (2001) studied individuals who 
had no previous use of OC. The individuals were randomly assigned either a monophasic OC 
(35 µg EE and 250 µg norgestimate) or triphasic OC (35 EE and 180, 215 µg and 250 µg 
norgestimate). The study assessed individuals prior to starting their OC use and reassessed at 
3, 6 and 12 months. During the initial assessment, prior to OC use, 57 % of individuals 
believed they suffered from PMS. When individuals were asked what the OCs effect was on 
PMS after OC use, more females perceived that it helped alongside this, those that perceived 
the pill made PMS better also indicated that OC use reduced menstrual pain. Similarly, Boyle 
and Grant (1992) who demonstrated that 79% of OC users believed that physical symptoms 




increase possibilities for expectancy effects. Abraham, Luscombe, and Soo (2003) found that 
non-OC users reported more frequent tiredness and fatigue compared to OC-users. It should 
be noted that differences in OC formulations could affect the conclusions drawn between the 
literature, with monophasic and triphasic formulations potentially having different effects on 
somatic and/ or affective symptoms. Ross, Coleman, and Stojanovska (2003) investigated 
this theory and found that somatic symptoms and fluid retention were reported at a higher 
rate for monophasic OC users. Although, Bruni et al. (2000) found that the adverse effects of 
monophasic and triphasic OC users were similar.  
 
Moreover, during the withdrawal week, several studies have noted that although OC users 
reported a lower severity of symptoms compared to non-oc users, they still experienced 
changes throughout the 28-day cycle, particularly during the premenstrual and menses phase 
(Adan, Prat, Fabbri, & Sànchez-Turet, 2008; Coffee, Sulak, & Kuehl, 2007; Hamstra, de 
Kloet, de Rover, & Van der Does, 2017; Sulak, Kuehl, Ortiz, & Shull, 2002; Yonkers, 
Cameron, Gueorguieva, Altemus, & Kornstein, 2017), it is therefore of interest to look into 
the cyclic changes that may occur during the 28 day period, looking at comparing both the 
consumption and withdrawal period and within the withdrawal period (the start and the end).  
  
Rewards & motivation  
Oral contraceptives have the ability to reduce testosterone levels within the body, by 
increasing levels of sex-hormone-binding globulin (SHBG), which decreases free 
testosterone levels, alongside altering other physiological processes (Greco, Graham, 
Bancroft, Tanner, & Doll, 2007; Vibarel-Rebot, Rieth, Lasne, Jaffré, & Collomp, 2015; 
Zimmerman et al., 2014). As mentioned within the non-oc section, testosterone is involved in 
motivation and therefore it would be reasonable to assume that low levels of testosterone are 
associated with lower levels of motivation to train and higher levels of perceived effort to 
train (Cook & Beaven, 2013; Crewther, Hamilton, Casto, Kilduff, & Cook, 2015). Moreover, 
as mentioned within the non-oc literature review if females experience premenstrual and 







Methods for validating menstrual cycle phase 
 
Tracking the menstrual cycle is important, as it helps to determine which phase the female is 
in. However, it should be noted that even in eumenorrheic females regular hormone 
concentration fluctuations cannot be assumed and therefore testing is vital to help validate the 
hormones (Scheid & De Souza, 2010).  
 
Self-report/calendar-based counting  
Calendar-based counting is an indirect self-reported onset of menses, which helps to 
determine the menstrual phases by counting the onset of menses as day 1 of the cycle and 
then counting the days from that point.  Many studies have used self-report/calendar-based 
counting methodology to help track the menstrual cycle (De Jonge et al., 2019); with most 
studies using it as supplementary information alongside other scientific methodology to 
confirm cycle phase, as self-reports can be unreliable and lack in validity (Johnson, Miro, 
Barrett, & Ellis, 2009; Small, Manatunga, & Marcus, 2007; Wideman, Montgomery, Levine, 
Beynnon, & Shultz, 2013). Moreover, self-reports are retrospective in nature, as the days 
need to be counted backwards to predict phases, which is not useful for a prospective 
research study where testing is required within certain phases. It is also challenging to 
estimate when ovulation occurs due to the retrospective nature. Additionally, many studies 
lack a clear, coherent definition to state the beginning of menses, which is required to 
eliminate subject error in dating the onset of menses (Slauterbeck et al., 2002; Taffe & 
Dennerstein, 2000).  
 
Basal body temperature 
Since there are predictable changes in BBT across menstrual cycle phases (as discussed in 
thermoregulation section), it is possible to use regular temperature monitoring (e.g., daily 
logging of BBT) to predict phases.  
 
Urinary LH measurement  
 As previously mentioned, ovulation is triggered by a surge in LH (Yoshimura & Wallach, 
1987). Detection and tracking of the female ovulation day would help researchers determine 
when the female has entered the luteal phase (Eichner & Timpe, 2004). The LH surge can be 




(Gudgeon, Leader, & Howard, 1990; Katler, Tricarico, & Bishop, Lauren, 2018). With this 
form of methodology, the individual urinates on the test stick or places the stick into 
collected urine, dependent on the form of ovulation kit. The stick will then turn a certain 
colour or display a positive sign if LH surge is detected. To detect LH surge, urinary LH tests 
are used a few days prior to predicted ovulation and continued until a positive result occurs. 
Once LH surge is detected, ovulation usually occurs within 24 – 36 hours (Miller & Soules, 
1996; “What is Ovulation? The What, When and How – Clearblue,” n.d.). A few studies have 
used this method to help detect ovulation when investigating the effects of the menstrual 
cycle on sport (Forsyth & Reilly, 2008; Hertel, Williams, Olmsted-Kramer, Leidy, & 
Putukian, 2006; Romero-Moraleda et al., 2019; Tsampoukos, Peckham, James, & Nevill, 
2010). Park, Goldsmith, Skurnick, Wojtczuk, & Weiss (2007) however, advises caution when 
using urinary LH to detect ovulation. Their study demonstrated that LH surges across 43 
women varied in amplitude, duration and configuration. Moreover, they discovered that not 
all LH surges result in ovulation occurring even if the female has a regular menstrual cycle. 
The study concluded that, LH surge is defined by ≥ 2.5-fold increase from baseline and can 
last a duration of 5 – 11 days. Furthermore, at home testing can result in false-positive results 
(Ghazeeri, Vongprachanh, & Kutteh, 2000; McGovern et al., 2004) falsely indicating 
ovulation occurred when it did not. Therefore, it is suggested that other methods are used to 
help verify menstrual phase. 
 
It is suggested that the methodology used to measure the menstrual cycle changes in a 
practical setting should be non-invasive, inexpensive, easily available and easy to use (Su et 
al., 2017). Whereas when in a research setting, the main priority is that the methodology is 
accurate and valid. It is thought that a combination of different methods might be able to lead 












The project has 3 aims: 
Aim one: to determine if menstrual cycle phase or oral contraceptives use influences body 
temperature 
Aim two: to determine if menstrual cycle phase or oral contraceptives use influences mood 
and/or somatic symptoms  
Aim three: to determine the utility of self-monitoring methods, such as self-report/calendar 






























 Participants  
16 participants took part in the study (9 non-OC and 7 OC users). However, only 10 (4 non-
OC and 6 OC users) participants met the inclusion criteria for the data analysis. See table 2 
for participant characteristics and table 3 for reasons for participant exclusion. The volunteers 
were recruited through the university of Kent school email system, word of mouth and 
advertisements. All participants were healthy, free from injury and with no known 
neurological or cardiovascular diseases. All participants recruited were either experiencing 
normal menstrual cycles (free from OC use for at least 3 months) or using a monophasic OC 
for at least 3 months. Written consent was obtained, in line with Declaration of Helsinki, and 
the study was approved by the research Ethics and Advisory Group of the School of Sport 
and Exercise Sciences, at the University of Kent (Prop 37_2019_20). Participants logged and 






















Table 2. Participant characteristics 
Variable Range, Mean ± SD 
Non – OC group. N = 4 
Age (years) 23 – 27, 24.8 ± 1.7 
Height (cm) 158 – 183, 166.8 ± 11.2 
Body mass (kg) 56.2 – 100, 75.8 ± 18.1 
Cycle length (days) 27 – 28, 27.58 ± 0.42 
Follicular phase (days) 12.5 – 17.5 (13 – 18 days), 14.82 ± 1.10  
Luteal phase (days) 10.5 – 14.5 (11 – 15 days), 12.75 ± 1.73 
Menses length (days) 3.5 – 4.7 (4 – 5 days), 4.1 ± 0.5 
First peak (day) 11.5 – 16.5 (12 – 17 days), 13.8 ± 2.1 
EDO (day) 12.5 – 17.5 (13 – 18 days), 14.8 ± 2.1 
LH spike length (days) 1.3 – 4 (1 – 4 days). 2.3 ± 1.2 
Physical activity (minutes/day-1) Light intensity – 75 – 599, 264.7 ± 290.4 
 Moderate intensity – 45 – 180, 115.0 ± 67.6 
 Vigorous intensity – 35 – 150, 61.7 ± 78.5 
OC group. N = 6 
Age (years) 20 – 48, 30.2 ± 9.7 
Height (cm) 170 – 182, 171.7 ± 5.8 
Body mass (kg)  60 – 94, 73.8 ± 12.02 
Menses length (days 3 – 5.3 (3 – 5 days), 4.0 ± 0.8 
Type of OC Monophasic  
Brand of OC 20 – 35µg EE / 75µg – 3mg of progesterone (gestodene, 
levonorgestrel, drospireone, desorgestrel and norgestimate) 
Physical activity (minutes/week-1) Light intensity – 30 – 240, 103.3 ± 77.6 
Moderate intensity – 105 – 300, 208.0 ± 88.2 








Table 3. Participant exclusion 
Number of participants  Reason for exclusion  
2  Anovulatory cycles  
4 Data missing  
 
 Data collection  
Menstrual cycle was assessed through a combination of measures, including basal body 
temperature, urinary luteinising hormone detection, self-report logs and menstrual history. 
Participant physical activity was assessed through physical activity logs.  
 
All participants recorded their BBT using an oral digital thermometer (Clinical thermometer, 
One Step, Home Health UK) upon waking each morning through the entire duration of 
enrolment. Eumenorrheic participants were instructed to test for a urinary LH ‘spike’ (in 
order to identify the point of ovulation) at home from day 9 post onset of menses (self-
reported) daily for 10 consecutive days. The LH (ovulation) kits (Urine test strip, 
20mIU/mL 2.5mm, One Step, Home Health UK) were used to detect a surge in urinary 
luteinizing hormone that occurs prior to ovulation. Each participant was asked to collect their 
sample at the same time each day (10:30 am, to minimise potential confounding effects of 
diurnal variations or at a regular time slot between the hours of 10am – 8pm- i.e., regardless 
of the time, to ensure that it was the same time each day), and ensured they reduced their 
fluid intake 2 hours prior to sample collection to reduce potential confounding effects of 
fluid-induced diuresis leading to overly dilute urine samples. See appendix F. 
 
All participants self-reported their menstrual cycle. Clear guidelines were set to define the 
menstrual cycle, onset of menstruation and the end of menstruation. The menstrual cycle is 
defined as the number of days between the first day of menstrual bleeding of one cycle to the 
day before the onset of menses of the next cycle (NHS, 2016). Onset of menses is defined as 
day 1 of menstrual bleeding whereby feminine protection (i.e., sanitary towels etc.) is 
required. This statement was used to try and avoid participant error in dating the onset of 
menses and help differentiate from spotting (Lovering & Romani, 2005; Slauterbeck et al., 
2002). The end of menses is defined as the last day in which feminine protection is needed. 




(e.g., if menses commences before midday, that day is recorded as day 1, and if it commences 
after midday, the following day is recorded as day 1). See table 4.  
 
Table 4. Defining onset and end of menstruation. 
Onset of menses 
If bleeding starts before 12:00 midday It is classified as day 1 of your period 
If bleeding starts after 12:00 midday  The following day is classified as day 1 of your period 
End of menses 
If bleeding ends before 12:00 midday It is classified as end of your period 
If bleeding ends after 12:00 midday The following day is classified as end of your period  
 
Questionnaires   
 
Participants completed a variety of questionnaires (menstrual history, menstrual distress 
questionnaire, Brunel Mood Scale [BRUMS] and readiness to invest effort) during each 
menstrual cycle, the days in which questionnaires were completed differed between the two 
groups (Non-OC and OC-users). See table 5 for overview of study design.  
 
Menstrual history and Menstrual Distress Questionnaire (see appendix B & E) 
The menstrual history questionnaire was used gain more information about the individual’s 
menstrual cycle, including the length of the menstrual cycle, the length menses, frequency of 
cycles oral contraceptive use (and brand) and symptoms experienced during the menstrual 
cycle. The information was then used to assess if the individual met the inclusion criteria.  
 
The MDQ prospective questionnaire is a multivariate self-report inventory designed to 
capture the symptoms of psychological changes throughout the menstrual cycle (Moos, 
1968). The MDQ comprises of 47-items split into 8 sub scales: pain, water retention, 
autonomic reactions, impaired concentration, behaviour changes, negative affect, arousal and 
control. Boyle (1992) has provided evidence of validity of the MDQ. Form T of the MDQ 
was used to gain a prospective understanding of how the individual is feeling at the present. 
Each symptom is rated on a 6-point Likert scale according to severity of experience (from 1 
being no reaction at all to 6 being acute or partially disabling). The prospective questionnaire 




Mood (Brunel Mood Scale) and Readiness to Invest Effort (see appendix C and 
D) 
The 24-items BRUMS questionnaire was used to measure 6 mood states (tension, depression, 
anger, vigour, fatigue and confusion) through a self-report inventory (Duncan & Oxford, 
2011; Terry & Lane, 2003). The current study also measured each participant’s readiness to 
invest physical and mental effort (Midgley, McNaughton, Polman, & Marchant, 2007) in 
regards to physical activity/training through visual analogue scales ranging from 0-10, with 
high scores reflecting greater readiness to invest effort (Nyenhuis, Stern, Yamamoto, 
Luchetta, & Arruda, 1997; Tenenbaum et al., 2005). If participants were not completing 
physical activity on the day of recording, they were instructed to rate it on a scale as if they 


























Table 5. Overview of study design 
Eumenorrheic females OC users 
Menstrual history questionnaire 
BBT (every morning) 
Self-report logs – see appendix G and H  
Physical activity logs 
LH test 
From day 9 post onset of menses (self-reported) daily 
for 10 consecutive days or shorter, if spike detected 
and then subsided before day 10. 
 
MDQ prospective 
Every day  Every day of pill withdrawal phase  
BRUMS & Readiness to invest effort 
Days 2 – 4 post onset of menses. To represent early 
follicular /menses phase 
Days 8 – 10 of pill consumption phase 
Day 9+ until ovulation confirmed. To help estimate 
day of ovulation 
Days 5 – 7 of pill withdrawal phase  
+7 days after ovulation confirmed. To represent mid 
luteal phase  
 
2 – 3 days prior to onset of predicted next menses. To 
represent late luteal phase / premenstrual phase  
 
Statistical analysis  
Statistical tests were performed using IBM SPSS Statistic 27 software package (IBM, SPSS 
software, Chicago, IL) and descriptive data is presented as mean ± SD. Regarding the Non-
OC group, data including, BBT and positive LH, MDQ, Brums and readiness to invest 
physical and mental effort was analysed using 1-way repeated measures analysis of variance 
(ANOVA) in an attempt to highlight any differences across the set time points / phases. 
When significant main effects were identified, post hoc analysis was used. Paired t-tests were 
used to assess difference in BBT across two phases of the menstrual cycle (follicular phase 
vs. luteal phase and mid follicular phase vs. mid luteal phase).  A significance was accepted 
when p ≤ 0.05. Cohen’s D was used to measure effect size between means of premenstrual 




group two divided by pooled standard deviations for two groups (d = M1 – M2 / Spooled). 
Threshold values used were: <0.2 = small effect; 0.5 = medium effect; ≥ 0.8 = large effect. 
 
Regarding the OC group, paired t-tests were used to assess differences across two phases, 
consumption phase vs. withdrawal phase, in BBT, Brums and readiness to invest physical 
and mental effort, and between the start of withdrawal phase vs. end of withdrawal phase, in 
MDQ. A significance was accepted when p ≤ 0.05.  
 
The data was checked for normality (Shapiro-Wilk test). If this was violated, log-
transformations were performed. If log transformations did not normalise data, the Friedman 
test was performed and the non-parametric Wilcoxon matched-pairs was performed. The 
following parameters were normalised by log transformation: OC users: behavioural change 
and anger. The following parameters could not be normalised so were analysed with non-
parametric tests: non-OC: autonomic reactions, water retention, anger, depression, fatigue 
and tension; OC users: pain, autonomic reactions, control, confusion, depression and vigour.  
 
Standardisation of procedures  
Follicular phase length was defined as the first day of recorded menstruation to the estimated 
day of ovulation (EDO) (Bull et al., 2019). The luteal phase length was defined as the day 
after the EDO to the day before the next day of recorded menstruation. EDO was defined as 
















IV. Results  
Eumenorrheic results  
 
BBT & positive LH test  
The 1-way ANOVA revealed no significant effect between BBT and positive LH test (P = 
0.171). A few participants had multiple positive tests recorded in one cycle. Only the first 
positive test logged within the cycle was used to EDO, as the duration of the LH surge 
detected by the LH tests can vary across women.  
 
Majority of participants demonstrated a slight decrease in temperature prior to 1st LH spike 







































Pre ovulatory temperature Post ovulatory temperature
Cycle Phase




BBT & follicular Vs. luteal phase  
A paired samples t-test revealed no significant difference between BBT in the follicular or 
luteal phase (P = 0.073), with the average temperature 36.38 ± 0.09°C and 36.57 ± 0.08 °C in 
the follicular and luteal phase, respectively, a difference of 0.19°C.  
 
BBT & Mid follicular Vs. Mid luteal phase  
A paired samples t-test revealed no significant difference between BBT in the mid follicular 
or mid luteal phase (P = 0.112), with the average temperature 36.32°C and 36.63°C in the 
mid follicular phase and mid luteal phase, respectively, a difference of 0.31°C. Mid follicular 
phase was defined as day -7 to -3 before positive test and mid luteal phase was defined as day 
+6 to +10 days following positive test, with ovulation day as 0.  
 
Individuals who demonstrated a difference between follicular & luteal phase demonstrated a 




MDQ & premenstrual, early follicular, late follicular and luteal phase.  
The MDQ comprises of 47-items, however for the purpose of this study, “change of eating 
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Table 6 MDQ across premenstrual early follicular, late follicular and luteal phase 









Mean ± SD 
Range 
 
9.5 ± 3.2 12.7 ± 4.4 9.5 ± 2.8 9.8 ± 3.2 
7 – 14 9 – 18 7 – 13 7 – 14 
Concentration 
Mean ± SD 
Range 
 
12.3 ± 3.1 12.8 ± 3.9 12.5 ± 3.3 12.5 ± 3.4 
8 – 15 8 – 17 8 – 16 8 – 16 
Behavioural change 
Mean ± SD 
Range 
 
7.8 ± 2.1 9.0 ± 2.6 8.6 ± 2.7 8.0 ± 2.2 
5 – 9  6 – 12  5 – 10  5 – 10 
Autonomic reactions 
Mean ± SD 
Range 
 
4.4 ± 0.8 5.1 ± 0.9 5.0 ± 1.2 4.7 ± 1.1 
4 – 6  5 – 6  4 – 7  4 – 6  
Water retention  
Mean ± SD 
Range 
    
5.8 ± 1.7 6.6 ± 1.6 5.5 ± 1.2 5.6 ± 1.4 
5 – 8 5 – 9  4 – 7  5 – 8  
Negative affect 
Mean ± SD 
Range 
 
12.6 ± 4.1 13.2 ± 3.3 12.7 ± 3.8 13.1 ± 4.3 
8 – 17  10 – 17  9 – 16  8 – 17  
Arousal 
Mean ± SD 
Range 
 
12.1 ± 5.7 10.3 ± 3.8 11.1 ± 4.2 11.6 ± 5.3 
6 – 19  7 – 16  6 – 16  6 – 18  
Control 
Mean ± SD 
Range 
 
6.9 ± 1.1 6.9 ± 0.8 7.1 ± 1.3 6.8 ± 1.0 
6 – 8  6 – 8  6 – 9  6 – 8  
Premenstrual phase – average of 7 days prior to onset of menses. Early follicular phase – day of menses onset to 
end of menses. Late follicular phase – after menses to EDO. Luteal phase – day after EDO to the day prior to 





For pain, the 1-way ANOVA revealed a significant effect of phase (P = 0.001). However, 
post hoc paired t-tests did not identify any specific phase differences (all P > 0.05). The 
average pain score appeared highest, however, in the early follicular phase (termed menses), 
with a large effect size (Cohen’s d – 0.88) observed for the difference between means of 
premenstrual and early follicular phases. See table 6. 
 
Analysis revealed no significant difference for concentration (P = 0.436), behavioural change 
(P = 0.320), autonomic reactions (P = 0.052), water retention (P = 0.221), negative affect (P = 
0.337), arousal (P = 0.187) and control (P = 0.590) across the menstrual phases.  
 
Brums & menses, day of 1st positive LH and 7 days after 1st positive LH 
The was so significant difference across the menstrual cycle for anger (P = 0.150), confusion 
(P = 0.160), depression (P = 0.223), fatigue (P = 0.368), tension (P = 0.497) and vigour (P = 
0.811). See table 7. 
 
Readiness to invest physical and mental effort during menses, day of 1st positive LH and 
7 days after 1st positive LH   
The 1-way ANOVA revealed no significant difference across the menstrual cycle for 



















Table 7 BRUMS across menses, 1st positive LH and 7 days after 1st positive LH 
Menstrual phase 
Subscale Menses (days 2 – 4) 1st Positive LH 7 days after 1st positive LH  
Anger 
Mean ± SD 
Range 
 
2.1 ± 1.6 0.5 ± 0.5 1 ± 1.2 
1 – 4  0 – 1  0 – 2  
Confusion 
Mean ± SD 
Range 
 
2.3 ± 1.9 1.8 ± 1.5 1.4 ± 1.7 
0 – 5  1 – 4  0 – 3 
Depression 
Mean ± SD 
Range 
 
2.3 ± 1.2 0.5 ± 0.9 0.7 ± 0.6 
0 – 4   0 – 2   0 – 1  
Fatigue 
Mean ± SD 
Range 
 
4.9 ± 1.7 3.2 ± 2.0 1.9 ± 2.4 
3 – 7 1 – 5  1 – 5 
Tension 
Mean ± SD 
Range 
 
4.4 ± 3.1 3.7 ± 3.2 3.3 ± 3.7 
1 – 6  0 – 6  0 – 7  
Vigour 
Mean ± SD 
Range 
 
2.6 ± 0.7 3.8 ± 3.4 4.5 ± 4.0 
1 – 4  0 – 7  2 – 9  
 
Table 8 Readiness to invest physical and mental effort during menses, day of 1st positive LH and 7 days after 1st 
positive LH 
Menstrual phase 
Subscale Menses (days 2 – 4) 1st Positive LH 7 days after 1st positive LH  
Physical Effort 
Mean ± SD 
Range 
 
63.1 ± 17.3 67.0 ± 21.2 75.2 ± 4.5 
40 – 77 46 – 86 71 – 79 
Mental Effort 
Mean ± SD 
Range 
 
67.6 ± 14.6 78.2 ± 8.5 83.5 ± 13.0 




Oral contraceptive user results   
 
BBT and consumptions vs. withdrawal phase  
A paired samples t-test revealed no significant difference between BBT in the consumption 
and withdrawal phase (P = 0.388), with the average temperature 36.20 ± 0.28°C and 36.25 ± 
0.25°C in the consumption and withdrawal phase, respectively, a difference of 0.05°C. 
Consumption phase was defined as the 21 days of active pill consumption and withdrawal 
phase was defined as the 7 days of placebo/no pill consumption 
 
MDQ and start of withdrawal phase vs. end of withdrawal phase  
Analysis revealed no significant difference for pain (P = 0.564), concentration (P = 0.695), 
autonomic reactions (P = 0.317), water retention (P = 0.076), negative affect (P = 0.907), 
arousal (P = 0.224) and control (P = 0.083). See table 9. 
 
A paired samples t-test revealed a significant difference between the start and end of 
withdrawal phase (P = 0.001) for behavioural change. Behavioural change was higher at the 
start of the withdrawal phase compared to the end of withdrawal phase (6.8 ± 2.0 vs. 6.3 ± 
2.0, respectively). The behavioural subscale in the MDQ is comprised of symptoms including 
lowered school or work performance, take naps/stay in bed, stay at home, avoid social 
















Table 9. MDQ and start and end withdrawal phase. * P < 0.05. 
 Withdrawal phase 
Subscale Start of phase End of phase 
Pain 
Mean ± SD 
Range 
 
11.5 ± 4.6 11.4 ± 4.2 
8 – 17 8 – 17 
Concentration 
Mean ± SD 
Range 
 
11.0 ± 2.5 10.7 ± 2.5 
8 – 14 9 – 14 
Behavioural change * 
Mean ± SD 
Range 
 
6.8 ± 2.0 6.3 ± 2.0 
5 – 10 5 – 10 
Autonomic reactions 
Mean ± SD 
Range 
 
4.6 ± 0.5 4.8 ± 0.7 
4 – 5 4 – 6 
Water retention 
Mean ± SD 
Range 
 
6.4 ± 3.0 5.4 ± 2.1 
4 – 12 4 – 9 
Negative affect 
Mean ± SD 
Range 
 
13.4 ± 5.2 13.3 ± 6.6 
9 – 21 8 – 24 
Arousal 
Mean ± SD 
Range 
 
8.9 ± 3.1 8.1 ± 2.9 
5 – 13 5 – 13 
Control 
Mean ± SD 
Range 
 
7.2 ± 1.7 6.8 ± 1.2 
6 – 10 6 – 9  









BRUMS and consumptions vs. withdrawal phase  
Analysis revealed no significant difference between consumption phase and withdrawal 
phase for anger (P = 0.770), confusion (P = 0.655), depression (P = 0.414), fatigue (P = 
0.253), tension (P = 0.135) and vigour (P = 0.104). See table 10. 
 
Table 10 BRUMS across consumption and withdrawal phase 
 Oral contraceptive phase 
Subscale  Consumption phase Withdrawal phase 
Anger 
Mean ± SD 
Range 
 
0.7 ± 0.8 15 ± 2.7 
0 – 2 0 – 7 
Confusion 
Mean ± SD 
Range 
 
1.0 ± 1.8 1.3 ± 2.1 
0 – 5 0 – 5 
Depression 
Mean ± SD 
Range 
 
0.5 ± 0.9 1.5 ± 2.1 
0 – 2 0 – 6 
Fatigue 
Mean ± SD 
Range 
 
2.9 ± 2.1 3.9 ± 1.9 
0 – 6 2 – 7 
Tension 
Mean ± SD 
Range 
 
1.9 ± 1.9 2.8 ± 2.5 
0 – 5 0 – 7  
Vigour 
Mean ± SD 
Range 
 
5.0 ± 2.7 3.3 ± 0.5 











Readiness to invest physical and mental effort across consumptions and withdrawal 
phase  
No significant difference was revealed for readiness to invest physical (P = 0.257) and mental 
effort (P = 0.069) between the consumption and withdrawal phase. See table 11. 
 
Table 11 Readiness to invest physical and mental effort across consumption and withdrawal phase 
 Oral contraceptive phase 
Subheading  Consumption phase Withdrawal phase  
Physical effort 
Mean ± SD 
Range 
 
72.1 ± 14.7 72.1 ± 15.6 
49 – 87.5 48 – 86.3 
Mental effort 
Mean ± SD 
Range 
 
63.4 ± 28.5 60.6 ± 25.6 
























V. Discussion  
The purpose of this study was to determine if menstrual cycle phase or monophasic oral 
contraceptive use influenced body temperature, mood and somatic symptoms. We also aimed 
to investigate the utility of self-monitoring methods including self-report/calendar based, 
BBT and urine LH measurements. Participants logged and tracked their menstrual cycles 
over 2 – 3 months (or 2 – 3 complete menstrual cycles), using at home data collection 
methods including BBT, urinary luteinising hormone detection kits and self-report logs. 
Participants also completed several questionnaires throughout each cycle, including MDQ, 
BRUMS and readiness to invest physical and mental effort. The current study found that 
BBT, mood and somatic symptoms did not differ across the menstrual cycle. The similarity 
between the two distinct phases in the menstrual cycle found in the current study disagrees 
with the findings of others. In line with previous findings, we failed to find significant 
differences for the majority of parameters measured for OC users either between the OC 
consumption phase and OC withdrawal phase or between the start and end of the OC 
withdrawal phase. Although, interestingly, a significant difference was found in behavioural 
change between the start and end of withdrawal week in OC users.  
 
Body temperature and eumenorrheic females  
 
In the current study, we compared BBT between the follicular and luteal phase and the mid 
follicular and mid luteal phase, both comparisons showing no significant difference. This 
contrasts with findings of Dutton, Blanksby, and Morton (1989) who found that BBT 
increased significantly between the follicular phase and luteal phase, with a difference of 
0.32°C. Similarly, Schoene, Robertson, and Pierson (1981) noted a significant difference 
between the mid follicular and mid luteal phase with a difference of 0.5°C. It should be 
noted, however, that participants in Schoene, Robertson, & Pierson's (1981) study, measured 
BBT at resting on test days compared to in the morning before getting out of bed, when 
temperatures lower. Refinetti (2010) demonstrated that body temperature increases 
throughout the day and is influenced by environmental and biological factors. Moreover, 
significant differences between the two main phases have been found by other researchers 
(Baker, Mitchell, et al., 2001; Baker, Waner, et al., 2001; Cagnacci et al., 2002; Shechter, 
Varin, & Boivin, 2010; Vidafar et al., 2018). Although it should be highlighted that a 




temperature, compared to BBT, can be collected throughout the day/night to detect changes 
that occur at any time. Central thermometers, like those used when measuring core body 
temperature, have higher rates of accuracy and are considered the gold standard compared to 
peripheral thermometers, used when measuring BBT (Hernandez & Upadhye, 2016). BBT 
can be influenced by lifestyle factors such as stress, alcohol consumption, sleep, diet, 
nutritional factors, medications and illness (Barron & Fehring, 2005).  Moreover, as 
mentioned previously, BBT can be challenging to interpret, with many studies relying on 
experienced researchers to study the graphs. Similarly, Gudgeon, Leader, & Howard (1990) 
found that only 40% of participants in their study demonstrated a shift within one day and 
75% did within two days of the LH surge, and in 34% of individuals, the BBT charts differed 
by more than two days or were inconclusive. It is important to note that, caution should be 
taken when comparing results from studies that have used gold standard techniques and those 
that have not, as temperature readings may vary (Kelly, 2006; Rabinowitz, 1996).  
 
The rise in body temperature during the second part of the menstrual cycle has been 
attributed to the rise in progesterone levels during the luteal phase (Grant et al., 2020; Isreal 
& Schneller, 1950; Stachenfeld et al., 2000). Whereas the decrease in temperature during the 
follicular phase has been attributed to oestrogens hypothermic effect. Cagnacci et al. (2002) 
and Grant et al. (2020) however found that the best predictor of body temperature changes is 
the progesterone/estradiol ratio. The absence of significant findings in the current study may 
be due to the way in which temperature was measured i.e., measuring BBT rather than core 
body temperature. The latter method would have been impractical and unfeasible for the 
current study, whereas BBT measurements could be instructed clearly and carried out at 
home easily and were therefore deemed to be the best way to collect data.  
 
The current study also failed to find a significant difference in temperature across 8 time 
points surrounding the LH surge and EDO. As mentioned in the literature review, BBT has 
been seen to decrease, reaching its lowest point, approximately 1 day prior to the LH surge 
(Kawamori et al., 2019; Su et al., 2017; Tenan et al., 2016, 2013). The lack of significant 
findings in the current study may be due to the inaccuracy of the BBT, as mentioned above, 







 Luteinizing hormone analysis  
 
The mean LH spike in the current study occurred at 13.8 ± 2.1 days into the cycle, lasting 2.3 
± 1.2 days, with EDO occurring at 14.8 ± 2.1 days. Cole, Ladner, and Byrn (2009) measured 
the mean LH peak (the highest value in the peak period) which occurred at 14.7 ± 3.7 days, 
with a range of 10 – 20 days. Similar results were collected by Park, Goldsmith, Skurnick, 
Wojtczuk, and Weiss (2007) who found that the LH surge occurred on day 14.5 ± 3.6 
(defined as the first LH value with a visually marked increase compared to prior value). As 
mentioned in the literature review, it is important to note that even if participants experienced 
an LH surge, it does not necessarily mean they had an ovulatory cycle (Krotz et al., 2005). It 
is therefore useful to look at other markers, such as serum LH, FSH and estradiol, 
progesterone and urinary pregnanediol 3-glucuronide (Ecochard et al., 2013; Li, Chen, 
Overstreet, Nakajima, & Lasley, 2002) as well as urinary LH to determine if individuals 
experienced ovulatory cycles.  
 
In the current study, we asked participants to conduct LH tests at the same time each day 
(between the hours of 10:00-20:00, with the ideal standardised time of 10:30 am, to minimise 
potential confounding effects of diurnal variations). The guidelines were in line with the 
instructions on the LH at home test kits used (Urine test strip, 20mIU/mL 2.5mm, One 
Step, Home Health UK), which advised to avoid testing samples first thing in the morning, as 
LH would not yet appear in the urine due to synthesis occurring during the early morning. 
Krotz et al. (2005) investigated the time of day the LH surge occurs and found that most 
participants surged between 06:00-08:00 with lower surge rates occurring as the day goes on 
(08:00-19:00). Similar results were found by (Cahill, Wardle, Harlow, & Hull, 1998). It has 
been suggested that melatonin may be responsible for the timing of the LH surge. Melatonin 
is secreted form the pineal gland and is involved in sleep regulation and circadian rhythm 
amongst other things. Melatonin secretion increases during the evening, with darkness 
increasing production and light decreasing production, and peaks between 02:00 and 04:00 
before gradually decreasing into the early morning. Melatonin has been seen to act on the 
gonads, reducing the secretion of gonadotrophins including LH (Reiter, 1980) and therefore, 
during the early morning when melatonin levels are decreasing, the LH surge occurs (Cahill 
et al., 1998; Grivas, Vasiliadis, Mouzakis, Mihas, & Koufopoulos, 2006). It is therefore 
plausible that participants who did not experience an LH surge, and were regarded as 




later) when testing, or that it would have been more likely to detect higher levels/pick up the 
surge with earlier sample times. However, whilst it is possible that LH levels are higher 
earlier in the day, it may not have been enough to cause missed/false negative readings if 
individuals took their samples later in the day. Nevertheless, timing of LH tests would be 
something to consider in future research, with LH tests carried out earlier in the day 
compared to later in the day.  
 
To increase accuracy of testing, it would be advisable that participants carry out multiple LH 
tests through the day to aid in determining the most common time LH surges occur on an 
individual basis. However, this would increase the participant burden may also compromise 
study adherence. Furthermore, the LH test kits do not determine LH concentration, but rather 
only show positive vs negative based on a pre-determined threshold. This means that even if 
an individual receives a positive LH reading (i.e., sensitivity threshold is exceeded), it may 
not be the peak and therefore counting days using this method may prove inaccurate. A more 
accurate way would be to measure serum LH repeatedly throughout the day(s) (O’Connor et 
al., 2006), however this is an invasive technique and cannot be carried out by the participant 
themselves. Another repeated measure could be through collection of urine which can be 
analysed in a laboratory setting for LH concentration and/or other hormone assessments 
(Ecochard et al., 2013; Leiva, Bouchard, Abdullah, & Ecochard, 2018; H. Li et al., 2002). 
The above methods are however an extra burden to participants as multiple samples would 
need to be collected, stored and transported to a laboratory compared to using a LH stick 
which is able to give an instant result. It is worth noting that the majority of the studies 
mentioned are concerned with the fertility aspect of ovulation, but in the current study we 
used LH to confirm ovulatory cycles, to help distinguish between the two main phases. 
 
Psychological effects and eumenorrheic females  
 
Results of the repeated measures ANOVA indicated that 7 out of 8 symptom subscales in the 
MDQ did not differ significantly across the menstrual cycle phases (premenstrual, early 
follicular, late follicular and luteal phase). We did, however, discover a significant main 
effect of menstrual phase for pain (P = 0.001), although post hoc analysis did not identify any 
specific phase difference (all P > 0.05). The absence of significant difference between 
specific phases could be due to the sample size reducing the statistical power and chance of 




– 0.88) observed for the difference between means of premenstrual and early follicular 
phases, which would be in agreeance with previous literature. The pain subscale in the MDQ 
consists of 6 items (muscle stiffness, headache, cramps, backache, fatigue and general aches 
and pains) which are typically associated with menstruation. Mohamadirizi and Kordi (2013), 
through the use of the MDQ, discovered that females experienced pain throughout their 
menstrual cycle but particularly during bleeding, with 83.55% of females suffering during 
menses compared to 12.95% and 18.07% experiencing pain during pre-menstruation and post 
menstruation, respectively. Ross, Coleman, and Stojanovska (2003) found similar results. 
Their study found somatic symptoms, which included cramps, backache and general aches 
and pains, was higher during menses compared to the premenstrual phase. Comparable 
conclusions have been drawn by Boyle and Grant (1992), Heitkemper and Jarrett (1992), Lu 
(2001) and Van Den Akker and Steptoe (1985). However, we did not find any specific phase 
difference. 
 
In contrast to previous studies, negative affect did not differ significantly between menstrual 
phases. Negative affect has 8 items in the MDQ, including crying, loneliness, anxiety, 
restlessness, irritability, mood swings, depression, and tension. Similarly, negative subscales 
in the BRUMS, including depression, tension and anger did not differ between menstrual 
phases. Many studies have suggested that scores for negative mood state were statistically 
higher in the late luteal phase (premenstrual phase) compared to menses (early follicular 
phase) and late follicular phase. Gonda et al. (2008) studied healthy eumenorrheic females, 
over 3 complete menstrual cycles, using the prospective record of the impact and severity of 
menstrual symptoms (PRISM), the study found that > 50% of participants had ≥ 66% 
increase in physical symptom severity in the late luteal phase compared to the late follicular 
phase. Throughout the first menstrual cycle, participants completed a variety of 
questionnaires, including the state anxiety scale of the State Trait Anxiety Inventory (STAI), 
Symptom Distress Checklist 51 (SCL-51) and the Zung Self-rating depression scale at three 
time points: early follicular phase (3 – 4 days after onset of menstruation), the late follicular 
(8 – 10 days after onset of menstruation) and the late luteal phase (2 – 3 days preceding the 
onset of menses). The study found that scores for anxiety and depression were significantly 
higher in the late luteal phase compared to the follicular phase. Although, it should be 
highlighted that when the follicular phase was split into two subphases (early and late), SCL 
anxiety score were only significantly different when comparing the late follicular and late 




follicular and late follicular phase and late follicular and late luteal phase. Moreover, 
Ziomkiewicz et al. (2012) found that 75% of females reported an increase in aggression, 
irritation and depressive behaviour during the luteal phase. Ross et al. (2003) found that 
negative affect symptomology peaked on day 27 in naturally cycling females (cycles were 
standardised into a 28-day record).  
 
Mohamadirizi and Kordi (2013) conducted a retrospective questionnaire to analyse the 
association between menstruation and anxiety, depression and stress. The questionnaire 
results were split into three phases: menstrual signs a week before menstruation (luteal 
phase), during bleeding (menses) and a week after menstruation (follicular phase). The study 
found a positive correlation between the menstruation signs (including irritability, low back 
pain, fatigue, cramps) at all three time points and depression, anxiety and stress. Similar 
results were concluded by Nillni et al. (2013). Iqbal et al. (2021) found that 56.4% of women 
suffered with anxiety before or during menstruation, with 70.6% suffering with it before, 
27.8% during and only 16% after, highlighting that the majority of women suffer with 
anxiety in the luteal phase compared to the follicular phase  
 
In respect of psychological differences between participants, a number of studies have been 
carried out. Hardie (1997) conducted a study whereby females were blind to the menstrual 
cycle focus. Participants were instructed to complete a diary and questionnaires at the same 
time each day, either first thing in the morning or last thing in the evening. The diary 
entries/ratings reflected the previous 24 hours. The study used the counting method to 
determine participants menstrual cycle phase: premenstrual (7 days prior to onset of menses), 
menstrual (all days of bleeding), postmenstrual (7 days following menstruation) and 
intermenstrual (all remaining days). The study found that there was no recurrent pattern of 
premenstrual affective change over 2 cycles, even though 40% of participants perceived 
themselves to have PMS. Moreover, Balaha, Amr, Al Moghannum, and Al Muhaidab (2010) 
found that prevalence of anxiety and depression was significantly more evident in females 
who suffer with and are diagnosed with PMS, therefore to improve future research, studies 
should carry out preliminary testing on participants so that comparisons can be made fairly 
and accurately. Although, caution should be taken when analysing findings from studies that 
rely on the counting method to determine menstrual phases, as self-reports can be unreliable 
and lack in validity (Johnson, Miro, Barrett, & Ellis, 2009; Small, Manatunga, & Marcus, 




employing LH tests to confirm ovulatory cycles, anovulatory females could be included in 
the data.  
 
It is seems intuitive to assume that if females are experiencing somatic and affective 
symptoms during their menstrual cycle, particularly during the luteal and menses phase, this 
would have an effect on their readiness to exert physical and mental effort, whereas during 
the late follicular phase / ovulation, higher levels of effort/motivation may be expected (Cook 
et al., 2018). In the current study, however, we found no significant difference between 
menses, day 1 of positive LH test (late follicular/ovulation) and 7 days after positive test (mid 
luteal). It should be noted that readings for both physical and mental effort were higher, but 
not significant, 7 days after a positive LH test and lowest during menses. These findings are 
in contrast to the findings of Cook, Kilduff, and Crewther's (2018). They studied 22 athletes 
(elite and non-elite participants). Their participants were instructed to rate their motivation to 
train and compete on a Likert scale with 1 being no motivation train/compete and 7 being 
extremely motivated to train/compete. As would be expected, elite athletes had higher 
motivation to compete than the non-elite group. Moreover, the study found that both groups 
of athletes reported higher motivation to train on day 14 (ovulation) vs day 7 (follicular 
phase) and day 21 (luteal phase). It is important to highlight that the researchers only had 
participants self-report day 1 of their menstrual cycle (onset of menses) and then presumed 
day 14 would be ovulation day, however, as already mentioned, this methodology has its 
disadvantages. Li, Lloyd, and Graham (2020), however, investigated physical and mental 
fatigue across the menstrual cycle. They assessed individuals’ physical and mental fatigue 
severity using the fatigue and energy scale and found that physical fatigue remained 
unchanged throughout the cycle when looking at three time points (10-14 days prior to 
ovulation and 5-10 days after ovulation). Whereas mental fatigue significantly increased from 
early follicular phase to mid luteal phase. The authors noted that mental fatigue may be 
higher during the mid-luteal phase due to the rise in both oestrogen and progesterone.  
 
COVID-19 pandemic and the menstrual cycle  
 
In December 2019, COVID-19 spread all over the world, with a global pandemic declared in 
March 2020. The COVID-19 pandemic has had a significant impact on  the population’s 
mental health (Salari et al., 2020). Periods of psychological distress and stress can affect a 




body (Smith & Vale, 2006; Toufexis, Rivarola, Lara, & Viau, 2014), once activated, there is 
an increase in cortisol and corticotropin-releasing hormone levels, which can suppress normal 
levels of reproductive hormones (Kalantaridou, Makrigiannakis, Zoumakis, & Chrousos, 
2004), including LH, testosterone, oestrogen and progesterone. Phelan, Behan, and Owens 
(2021) found that as a result of the pandemic, women experienced reproductive health 
disturbances which were associated with a significant increase in suffering from mental 
health symptoms such as low mood, anxiety and poor concentration. The findings of Phelan, 
Behan, and Owens (2021) study are in agreeance with Demir, Sal and Comba (2021) in 
which anxiety scores were significantly higher during the pandemic compared to before the 
pandemic.  Moreover, they found that females experienced an increase in PMS symptoms 
compared to pre-COVID, with 53% stating a worsening in symptoms, 7% stating an 
improvement in symptoms and 40% stating symptoms were unchanged. Similarly, Takmaz, 
Gundogmus, Okten, and  Gunduz (2021) noted an increase in COVID-19 pandemic-induced 
anxiety, perceived stress and depressive symptoms. Comparable results were found by 
Bruinvels et al. (2021) when investigating eumenorrheic females and HC users.   
It is interesting to note that differences in results of the current study and those mentioned 
within the literature review and discussion may be due to psychological differences due to the 
data collection during the pandemic. Without hormone analysis, or baseline measures (both 
physiological and psychological) during normal/non-Covid times, it is challenging to make 
assumptions, although, the pandemic may have influenced the participants reproductive 
hormones which may have played a role in the study’s findings. For example, if testosterone 
levels were supressed, this may explain why no significant findings were found between the 
two phases within the menstrual cycle when looking at readiness to invest effort. In line with 
this, Bruinvels et al. (2021) highlighted that 59.3% of participants stated they experienced a 
lack of motivation during the pandemic.  
 
Body temperature and monophasic oral contraceptive users  
 
Our finding that monophasic OC users have similar temperatures across the two phases (pill 
consumption and withdrawal) are in agreeance with results produced by  Baker, Mitchell, and 
Driver (2001). However, in contrast, the OC pill consumption phase mean temperature was 
not similar to that of the non-oc luteal phase mean temperature (Baker, Mitchell, et al., 2001; 
Baker, Waner, et al., 2001). This may be due to the methodology differences, as both studies 




measured BBT in the morning using an oral thermometer. Discrepancies between the two 
methods and why it may have affected results can be read in the non-oc discussion section.  
 
Psychological effects and monophasic oral contraceptive users 
 
In the current study, we failed to find a significant difference between the start of the 
withdrawal phase and the end of the withdrawal phase in pain, concentration, autonomic 
reaction, water retention, negative affect, arousal and control. The findings are of interest as it 
demonstrated that during the first 5 days of withdrawal compared to the final 3 days of 
withdrawal no differences were found. Moreover, as the withdrawal bleed would have 
occurred during the withdrawal phase, starting in the first few days, it is interesting to note 
that individuals did not suffer from menstrual related symptoms that may have occurred. 
These findings are consistent with Sanders, Graham, Bass, and Bancroft (2001) who 
demonstrated that when compared to baseline measures (without the pill), oral contraceptives 
were perceived to reduce menstrual pain and other effects of menstrual related symptoms 
(Yonkers et al., 2017). Similarly, the concept that the oral contraceptives help stabilise the 
hormonal levels can be seen through the absence of significant differences between the 
consumption and the withdrawal phase for items of the BRUMS, including anger, confusion, 
depression, fatigue, tension and vigour, and in both subscales in the readiness to invest effort. 
In contrast, other researches have suggested that cyclic changes do occur throughout the 
cycle, particularly during the premenstrual and menses phase (Kelly et al., 2010; Walker & 
Bancroft, 1990), in OC users, although the changes are smaller when compared to non-oc 
users (Taggart et al., 2018; Yonkers et al., 2017). Hamstra, de Kloet, de Rover, and Van der 
Does (2017) found that during the pill withdrawal week, OC users reported increased 
irritability (Coffee, Kuehl, Willis, & Sulak, 2006). The increase in irritability may be due to 
the decrease in stabilising hormones, i.e., reduction in exogenous hormones, as recordings 
were completing on day 6 of the withdrawal week (Coffee et al., 2007; Kelly et al., 2010). 
The symptoms may increase during the withdrawal week due to exogenous hormonal 
concentrations decreasing and symptoms related to bleeding (Sulak et al., 2002). As 
mentioned in the literature review, the dose/type of progestin used may have an influence on 
whether females experience PMS symptoms / the severity of PMS experienced, Schultz-
Zehden and Boschitsch (2006) recommended using a combined oral contraceptive containing 
EE 20 µg and drospireone 3mg to help reduce/decrease premenstrual symptoms. Similarly, 




such as desorgestrel, gestodene and norgestimate (London, 1992; Wichianpitaya & 
Taneepanichskul, 2013). In the current study, five out of six participants were prescribed one 
of the above Ocs. It is possible, therefore, that the absence of cyclic changes in the current 
study are due to the dose of OC used. It would be of interest for future studies to look at other 
OC doses. Moreover, the variety of dose’s used in the current study highlight a limitation 
within the paper. It would have been more beneficial to recruit females who used the same 
type, brand and dose of OC for fair comparisons to be made with other studies.  
 
In contrast, a significant difference was seen in behavioural change, with changes greater at 
the start of the withdrawal phase compared to the end. Behavioural change includes lowered 
school or work performance, take naps/stay in bed, stay at home, avoid social activities and 
decreased efficiency. The start of the withdrawal phase would comprise the reduction and 
gradual decrease of exogenous hormones and a gradual increase of endogenous estradiol, 
although it should be noted that the change in endogenous hormones are not significantly 
different between the two phases (consumption and withdrawal) (Baker, Mitchell, & Driver, 
2001).  Moreover, the reduction of the exogenous hormones signals the start of the 
premenstrual and menses phase (withdrawal bleed) within the OC users. It would therefore 
be probable to assume that compared to the later end of the withdrawal phase, the women 
experienced symptoms such as a reduction in energy which would have influenced their 
behaviour i.e., staying in bed, taking naps and decreased efficiency. Although, it should be 
highlighted that when fatigue was examined through the BRUMS questionnaire, comparing 
consumption and withdrawal, there was no significant difference found. The inconsistencies 
within the results could be due to the fact that behavioural changes were only evident for the 
first half of the withdrawal period and were reduced dramatically towards the latter, which 
would therefore aid in highlighting why no significant difference was found in the BRUMS 
(recorded on days 5 – 7 in withdrawal phase). Furthermore, premenstrual symptoms tend to 
peak ~2 days prior to the onset of menses (Yonkers et al., 2008). In the current study, OC 
users had a mean menses start date of the 4th day in the withdrawal phase, therefore if 
symptoms were to occur and peak, it would be captured at the start of the withdrawal phase 










In interpreting the results of the current study, several limitations must be taken into account. 
The assessments made were through analysis of questionnaires and relied on self-report. Self-
report questionnaires can have great variability, as individuals may not know how to fill them 
in correctly and/or the individuals may be dishonest and give incorrect details. Moreover, due 
to the at home setting, we were not able to conduct serum hormone concentrations to validate 
the menstrual phase.  
 
As mentioned within the discussion, BBT recordings can be influenced by a variety of things 
(Barron & Fehring, 2005) that were not controlled in the current study. Furthermore, oral 
thermometers may not be as sensitive to temperature changes compared to central 
thermometers; central thermometers, have higher rates of accuracy and are considered the 
gold standard (Hernandez & Upadhye, 2016). Asadian, Khatony, Moradi, Abdi, and Rezaei 
(2016) demonstrated that when compared to nasopharyngeal temperature (inserted through 
the nasal cavity), the oral thermometer method had ‘acceptable precision’ in measuring body 
temperature although accuracy was lower. It should be highlighted that the aforementioned 
study is focused on the use of oral thermometers in a clinical setting, which was not the focus 
in the current study. BBT recording is useful, as patterns can be highlighted over several 
months of tracking, however it is advisable that BBT is used in conjunction with other 
tracking methods, such as urine LH which is a more appropriate method for identifying 
ovulation.  
 
The current study controlled the type of oral contraceptive, however we failed to control the 
brand and dose, which may have caused discrepancies within the data, even more so when 
comparing our findings to others. Moreover, due to time restraints, the current study was 
unable to compare findings between non-oc users and monophasic OC users. It would 
therefore be important for future studies to investigate if differences occurred between the 
groups.  
 
The sample size for both groups were low, which was unfortunate as it may have reduced the 
chance of detecting a true effect (Button et al., 2013). However, it was of utmost importance 




category, as discussed in the literature review, it is appropriate due to the differences in 
hormonal profile. 
 
As previously discussed, this study has been limited by the COVID-19 pandemic. The study 
design was affected, and data collection was limited to at home-based recordings compared 
to laboratory based assessments, such as hormone analysis. Moreover, the psychological 
differences due to the pandemic may have influenced the results, which is challenging in two 
respects; the results collected may not represent the true cyclic changes within the menstrual 
cycle and the outcomes found in the study may be difficult to compare to previous and future 
studies. On the other hand, this study is unique as it conducted research during a global 
pandemic and was able to test the utility of at home tracking methodologies, which can be 




The purpose of this study was to determine if menstrual cycle phase or monophasic oral 
contraceptive use influenced body temperature, mood and somatic symptoms. We also aimed 
to investigate the utility of self-monitoring methods such as self-report/calendar based, BBT 
and urine LH measurements. We found that BBT, mood and somatic symptoms did not differ 
across the menstrual cycle, which disagrees with the findings of others. We also failed to find 
significant differences for the majority of parameters measured for OC users either between 
the OC consumption phase and OC withdrawal phase or between the start and end of the OC 
withdrawal phase, with the exception a significant difference found in behavioural change 
between the start and end of withdrawal week. Moreover, the at home LH detection kits were 
effective, as participants were able to easily carry out and track their results. Although BBT 
recordings were simple to record, they were not effective in displaying temperature changes 
throughout the menstrual cycle in eumenorrheic females.  
 
It would be useful for future research to conduct a similar study, on a larger population, to 
determine whether there are differences across the menstrual cycle in eumenorrheic females 
and in monophasic oral contraceptive users. Moreover, the validity and accuracy of oral 
thermometers used to record BBT should be investigated. Oral thermometers are an 
inexpensive and easy to use tool that many individuals already use to track their cycle, either 




therefore it would be a beneficial research area to investigate for the wider population. 
Further research is required to determine if changes occur across the menstrual cycle, and if 
changes do occur then how may the fluctuations influence sporting performance. Finally, 
something to consider for future research would be the impact the global pandemic has had 
on the menstrual cycle and how it may influence individual’s psychology.  
 
Practical applications  
 
• Mood and somatic changes did not significantly differ across the menstrual cycle in 
naturally cycling women, these findings could further investigations into why some 
women may perceive changes rather than experience changes across the menstrual 
cycle.  
• Monophasic oral contraceptive users overall did not experience significant changes 
across their menstrual cycle (consumption and withdrawal phase), which may 
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a. Original study overview  
 
Inclusion criteria: 
Healthy, active females aged 18 – 55 years old, and males, aged 18-45 years old. The 
participants should be active and train at a vigorous intensity for 75 minutes or at a moderate 
intensity for 150 minutes per week (UK Chief Medical Officers, 2019). During testing, 
participants should maintain their normal weekly training schedule (and maintain at the same 
level, in terms of frequency, intensity, duration etc, for the duration of the study). Female 
participants should be experiencing normal menstrual cycles (free from oral contraceptives 
for at least 3 months) or using a monophasic oral contraceptive for at least 3 months 
 
Exclusion criteria:  
Cardiovascular, respiratory and neuromuscular disease and mental impairment; injury in the 
last three weeks and upper respiratory tract infection in the last 2 weeks.  
 
Pre-screening pilot and main study: 
 
A pre-screening questionnaire (PAR-Q) will be completed. Anthropometric measurements 
(height and body mass) and baseline heart rate (HR) will be recorded via a HR monitor 
located around the chest (BHIP 9 HR monitor, UK). If meetings are required, they will be 
conducted either on the SSES premises, or if more convenient for participants, in a mutually 
convenient public location with reference to the relevant risk assessments (SSESRA50: Off-
site testing at Sports clubs and facilities; SSESRA62: Out of hours working).   
 
Pilot study methodology   
The experimental design will be a single-blind study, as the participant will not know the % 









The first visit to Medway Park will be to familiarise the individuals with the protocol and 
equipment used during the trials. Pre-screening and anthropometric measurements, as 
mentioned above, will be completed.   
 
The participants will complete a standardised 5-minute warm up on the cycle ergometer 
(Excalibur Sport, Lode,  Groningen, The Netherlands) at a rating of perceived exertion of 11 
(RPE – Borg scale 6 -20) (Borg & Löllgen, 2001). A 5 second maximal sprint at 3 minutes 
will also be performed. Participant’s intensity (work rate) and cadence (rpm) at 11 RPE will 
then be used for subsequent warmups.  After 5 minutes of rest, participants will then be 
instructed to complete the RS protocol; 10 x 6 s maximal sprints, interspersed with 30 s 
active no load recovery. Each sprint will be performed in a seated position with their feet 
secured to pedals, either using toe straps on pedals, or cleats/cycling shoes if they have their 
own. All participants will be verbally encouraged during each sprint to give maximal effort. 
After 20 minutes of recovery an interval-based TTE  protocol, 30 s exercise, 30 s active no 
load recovery, will be completed at a fixed intensity: 25%, 30% 35% and 40% of peak power 
output (taken as an average of the first 2 RSA sprints).   
 
Criteria to terminate test:  
Participants will continue the interval protocol until volitional exhaustion (until they cannot 
continue any longer). Participants will need to keep at the target cadence during the fixed % 
of their PPO; if their cadence drops by > 10 rpm they will be given a warning and instructed 
to increase cadence back to the target otherwise the test will be ended. If they are able to 
increase, they may continue with a warning but if cadence drops > 10 rpm again the test will 
be ended (i.e., if they drop by > 10 rpm twice in the same interval the test will be terminated). 
The exact time of failure/withdrawal will be recorded (to the nearest second).   
 
Once all testing has been completed, participants will complete a 5-minute cool down. 
 
Experimental trials  
Testing will be conducted at a time convenient for the laboratory, researchers and 






As described above, the participants will perform a standardised warm up. A 5-minute rest 
will be given before the trial start. Each trial will consist of 10 x 6 s maximal sprints, 
interspersed with 30 s active no load recovery and an interval-based TTE  protocol, 30 s 
exercise, 30 s active no load recovery, will be completed at a fixed intensity. 
 
Standardisation of procedures 
You will be required to complete a food and activity diary for the 48 hours before the first 
experimental visit. You will be asked to repeat your food and fluid intake (and activity) as 
closely as possible in the 48 hours prior to future experimental visits.  
You will also be asked to refrain from caffeine-containing sources, alcohol and vigorous 
activity 24-hours prior to the trials. You will also be required to avoid food or beverages 
(except plain water) 3 hours prior to testing.  
 
Main study methodology: 
Methodology: 
The experimental design will be a counterbalance, randomised, double-blinded design. 
Females in the study will complete 6 visits to Medway Park, 2 familiarisation and 4 main 
trials and males will complete 5 visits to Medway Park, 1 familiarisation and 4 main trials 
(see figure 6). After female participants have expressed interest in the study, a meeting will 
be arranged to discuss tracking of the menstrual cycle (booklet logging and BBT measures) 
and also fill in the menstrual history questionnaire. Meetings will be conducted either on the 
SSES premises, or if more convenient for participants, in a mutually convenient public 
location with reference to the relevant risk assessments (SSESRA50: Off-site testing at 
Sports clubs and facilities; SSESRA62: Out of hours working).   
 
Familiarisation 
The first visit to Medway Park will be to familiarise the individuals with the protocol and 
equipment used during the trials. Participants will be given a caffeine consumption booklet 
(modified Landrums (1992) prospective questionnaire) in which they will need to complete 
for a 7-day period. Full instructions will be given to participants.  
A pre-screening questionnaire (PAR-Q) will be completed. Participants will then complete 
the following forms: motivation questionnaires, Brunel mood scale (BRUMS) and for 




Anthropometric measurements (height and body mass) and baseline heart rate (HR) will be 
recorded via a HR monitor located around the chest (BHIP 9 HR monitor, UK). Saliva 
samples will be collected and processed (e.g., rendering acellular) for storage and later 
analysis of genotype and salivary immune markers.  
 
The participants will then complete a standardised 5-minute warm up on the cycle ergometer 
(Excalibur Sport, Lode,  Groningen, The Netherlands) at a rating of perceived exertion of 
11(RPE – Borg scale 6 -20) (Borg & Löllgen, 2001). Participant’s intensity (work rate) and 
cadence (rpm) at 11 RPE will then be used for subsequent warmups. Participants will then 
have a 5-minute rest before RS protocol. Participants will be instructed to complete the RS 
protocol; 10 x 6 s maximal sprints, interspersed with 30 s active no load recovery. Each sprint 
will be performed in a seated position with their feet secured to pedals, either using toe straps 
on pedals, or cleats/cycling shoes if they have their own. All participants will be verbally 
encouraged during each sprint to give maximal effort.  After 10 minutes of recovery an 
interval-based TTE  protocol, 30 s exercise, 30 s active no load recovery, will be completed 
at a fixed intensity (35% of individuals PPO, with cadence equal to the preferred cadence 
determined in warm-up) (see figure 6). The PPO will be determined by taking the average of 
the first 2 sprints in the familiarisation RS performance.  
  
Criteria to terminate test:  
Participants will continue the interval protocol until volitional exhaustion (until they cannot 
continue any longer). Participants will need to keep at the target cadence during the intervals 
at 35% of their PPO; if their cadence drops by > 10 rpm they will be given a warning and 
instructed to increase cadence back to the target otherwise the test will be ended. If they are 
able to increase, they may continue with a warning but if cadence drops > 10 rpm again the 
test will be ended (i.e., if they drop by > 10 rpm twice in the same interval the test will be 
terminated). The exact time of failure/withdrawal will be recorded (to the nearest second).   
 
Once all testing has been completed, participants will complete a 5-minute cool down. 
 
Experimental trials  
Testing will be conducted at a time convenient for the laboratory, researchers and 
participants. The same time of day will be maintained for each participant throughout the 




water, then sit restfully for 10 min. Resting HR will be measured in the final 2 min and then 
saliva and blood samples collected. Next (84pprox.. 1-hour prior to testing), participants will 
ingest a capsule, containing either 6 mg.kg-1 body mass caffeine or placebo (microcrystalline 
cellulose). Participants will then complete the following forms: motivation questionnaires, 
BRUMS and for females exclusively the MDQ form T (Moos, 1968). 
 
40 - 45 minutes post capsule ingestion baseline HR will be recorded. 
 
As described above, the participants will perform a standardised warm up. A 5-minute rest 
will be given before the trial start. Each trial will consist of 10 x 6 s maximal sprints, 
interspersed with 30 s active no load recovery and an interval-based TTE  protocol, 30 s 
exercise, 30 s active no load recovery, will be completed at a fixed intensity (35% of 
individuals PPO).  
 
Immediately after the standardised cool down a blood sample will be taken (5 minutes post 
TTE). 9 minutes post TTE, participants will have 1 minute to drink / rinse their mouth with 
plain water, then sit restfully for 10 minutes. After 10 minutes, a saliva sample will be taken 









Figure 6 Schematic of original study - trial testing procedures 
Study design  
The study will be a crossover design, whereby each participant will service as their own 
control (Betts & Gonzalez, 2018) by ingesting a capsule containing either 6 mg.kg-1 body 
mass caffeine or placebo (microcrystalline cellulose). The placebo capsule will be similar in 
shape, size and tastes to the caffeine capsule. The study will be double-blind, as the 
participant and researcher will not know what each capsule contains, until after the study has 
Arrival to lab. 
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been completed (to avoid any unconscious bias or expectancy effects). A manipulation check 
will be implanted after each experimental trial.  
 
Randomisation of order will be completed by a computer generator . For females, during 
each cycle they will have a caffeine and placebo trial – the order of the substances within 
each phase of the menstrual cycle will be randomised. For males, it will be completely 
randomised with 2 trials of caffeine and placebo in any order (see table 2). Trials would take 
place in follicular (3 – 7 days post onset of menses) and luteal phase (20- 26 days post onset 
of menses) for naturally cycling females and consumption (7 – 21 days of OC consumption) 
and withdrawal phase ( 26 – 28 days in cycle) for oc users.  
 
Table 12 Original study - randomisation of order throughout study 
Female randomisation across trials  
Menstrual cycle 1 Menstrual cycle 2 
Trial 1 Trial 2 Trial 3 Trial 4 
Caffeine Placebo Caffeine Placebo 
Placebo Caffeine Placebo Caffeine 
Male randomisation across trials 
Trial 1 Trial 2 Trial 3 Trial 4 
Caffeine Caffeine Placebo Placebo 
Placebo Placebo Caffeine Caffeine 
Caffeine Placebo Caffeine Placebo 
Placebo Caffeine Placebo Caffeine 
 
Standardisation of procedures 
You will be required to complete a food and activity diary for the 48 hours before the first 
experimental visit. You will be asked to repeat your food and fluid intake (and activity) as 
closely as possible in the 48 hours prior to future experimental visits.  
You will also be asked to refrain from caffeine-containing sources, alcohol and vigorous 
activity 24-hours prior to the trials. You will also be required to avoid food or beverages 





b. Menstrual history questionnaire  
 
1. How long is your menstrual cycle on average? How many days from your first 
menstrual period to the next menstrual period? The length of the menstrual cycle is 
the numbers of days between the first day of menstrual bleeding of one cycle to the 
day before the onset of menses of the next cycle. 
 
 
2. How long are your periods? Day 1 of menstrual bleeding is when feminine protection 
(i.e., sanitary towels etc.) is required. The end of the period is defined as the last day 
in which feminine protection is required.  
            ____________________________________ 
 
3. Do you take any oral contraceptives? 
a. Yes  
If so, please name: _____________ 
b. No 
 
4. Do you have irregular periods? 
a. Yes  
b. No 
 
5. How often have you had your menstrual periods in the last year? 
a. Once every 20 days or less 
b. Every 21 – 27 days  
c. Every 28 – 35 days  
d. Every 36 – 50 days  








6. How many of the symptoms below do you experience during your menstrual cycle. 
Please tick all that are appropriate.  
 
Insomnia Confusion Anxiety Hot flashes Distractible Swelling (e.g., abdomen, breasts 
or ankles) 
Crying Headache Backache Nausea or 
vomiting 
Depression Change in eating habits 
Muscle stiffness Cramps Cold 
sweats 
Restlessness General aches and 
pains 
Busts of energy or activity 
Forgetfulness Dizziness or faintness Fatigue Irritability Mood swings Lowered motor co-ordination 
 
c. BRUMS questionnaire 
Below is a list of words that describe feelings. Please read each one carefully. Then place a 
cross in the box that describes HOW YOU FEEL RIGHT NOW. Make sure you answer 
every question.  
Date: 
  Not at all A little Moderately Quite a bit Extremely 
1 Panicky      
2 Lively      
3 Confused      
4 Worn out      
5 Depressed      
6 Downhearted      
7 Annoyed      
8 Exhausted      
9 Mixed-up      
10 Sleepy      
11 Bitter      
12 Unhappy      
13 Anxious      
14 Worried      
15 Energetic      
16 Miserable      
17 Muddled      
18 Nervous      
19 Angry      





d. Motivation questionnaire 
 
Date: 
Readiness to invest physical effort 
 
Please mark the line below with a single downward stroke to indicate how physically ready 





Readiness to invest mental effort 
 
Please mark the line below with a single downward stroke to indicate how mentally ready 
you are to invest effort in this task.
21 Tired      
22 Bad Tempered      
23 Alert      
24 Uncertain      
Not ready at all Complete readiness (ready give maximal effort) 




e. Menstrual distress questionnaire 
For each symptom choose the descriptive category listed below which best describes your 
experience of that symptom today. Circle the number of the category which best described 
your experience of the symptom today.  














1 Weight gain  1 2 3 4 5 6 
2 Insomnia 1 2 3 4 5 6 
3 Crying 1 2 3 4 5 6 
4 Lowered school or work 
performance  
1 2 3 4 5 6 
5 Muscle stiffness 1 2 3 4 5 6 
6 Forgetfulness 1 2 3 4 5 6 
7 Confusion 1 2 3 4 5 6 
8 Take naps or stay in bed 1 2 3 4 5 6 
9 Headache 1 2 3 4 5 6 
10 Skin disorders 1 2 3 4 5 6 
11 Loneliness 1 2 3 4 5 6 
12 Feelings of suffocation 1 2 3 4 5 6 
13 Affectionate 1 2 3 4 5 6 
14 Orderliness 1 2 3 4 5 6 
15 Stay at home from work or 
school 
1 2 3 4 5 6 
16 Cramps (uterine or pelvic) 1 2 3 4 5 6 
17 Dizziness or faintness 1 2 3 4 5 6 
18 Excitement  1 2 3 4 5 6 
19 Chest pains 1 2 3 4 5 6 
20 Avoid social activities 1 2 3 4 5 6 
21 Anxiety 1 2 3 4 5 6 
22 Backache 1 2 3 4 5 6 
23 Cold sweats 1 2 3 4 5 6 
24 Lowered judgment  1 2 3 4 5 6 
25 Fatigue 1 2 3 4 5 6 
26 Nausea or vomiting 1 2 3 4 5 6 
27 Restlessness 1 2 3 4 5 6 
28 Hot flashes 1 2 3 4 5 6 






f. Urine dipstick instructions  
SPECIMEN COLLECTION:  
We will ask you to start at some point between day 7 and 10 of your cycle (we will decide 
the specific day after we have gathered some preliminary information and discussed this 
with you). Once we identified what day you should begin testing you should then collect 
your urine on a daily basis for 10 consecutive days.   
 
Important points   
1. Do not use first morning urine samples as LH is synthesized in your body early in the 
morning. It will not show up in your urine until later in the day.  
2. The best time to collect your urine is between 10 am – 8 pm. Pick a regular time that suits 
you best. Ideally, for this study try to do this at 10:30 am each day (if this fits with the 
requirement below, to reduce fluid intake for around 2 h before the sample).  
30 Painful or tender breasts  1 2 3 4 5 6 
31 Feelings of well-being 1 2 3 4 5 6 
32 Buzzing or ringing in ears 1 2 3 4 5 6 
33 Distractible 1 2 3 4 5 6 
34 Swelling (e.g., abdomen, 
breast, ankle) 
1 2 3 4 5 6 
35 Accidents (e.g., cut finger, 
break dish) 
1 2 3 4 5 6 
36 Irritability 1 2 3 4 5 6 
37 General aches and pains 1 2 3 4 5 6 
38 Mood swings 1 2 3 4 5 6 
39 Heart pounding 1 2 3 4 5 6 
40 Depression (feeling sad or 
blue) 
1 2 3 4 5 6 
41 Decreased efficiency  1 2 3 4 5 6 
42 Lowered motor coordination 1 2 3 4 5 6 
43 Numbness or tingling in 
hands or feet 
1 2 3 4 5 6 
44 Change in eating habits 1 2 3 4 5 6 
45 Tension 1 2 3 4 5 6 
46 Blind spots or fuzzy vision 1 2 3 4 5 6 




3. Collect urine at about the same time each day. Reduce liquid intake about 2 hours before 
collecting your urine as a diluted urine sample can prevent the test from detecting LH 
surge.  
  
BEFORE YOU BEGIN 
1. Read the instructions thoroughly before you begin.  
2. Do not open the foil pouch until you are ready to begin the test.   
3. Make sure you have a watch, clock or timer ready.   
4. Make sure that the stick has been stored at room temperature (i.e., avoid keeping them 
in particularly hot areas, such as need heating or cooking appliances). 
TEST PROCEDURE:  
1. Determine the day to begin testing.   
2. Collect urine sample in a clean and dry container.  
3. To begin testing, open the sealed pouch and remove the strip. Do not remove the strip 
until you are ready to begin testing.  
4. With the arrows pointing downwards towards the urine, place the test strip vertically 
(straight) into the urine sample, for at least 10 seconds. DO NOT allow the urine to go 
above the MARK level line.    
5. Remove the strip from the urine and place on a clean, dry surface.   
6. Wait for coloured bands to appear. Depending on the concentration of LH in the urine 
specimen, positive results may be observed within 1 minute. However, to confirm 
negative results, the complete reaction time of 10 minutes is required. Results obtained 







INTERPRETATION AND RECORDING OF RESULTS: 
After each test, you must decide if you are having a L.H. surge. Please add the result to your 
daily log (record as either Positive or Negative). If the result is inconclusive, please repeat 1 
further time.  
To determine your result, you must compare the colour intensity of the test band to the control 
band. The control band is used to compare the test band against and also confirms that you 
have completed the test correctly.    
Positive for L.H. surge  
If two colour bands are visible and the test band is of almost equal or greater colour 
intensity (darker) than the control band, this is a positive result and a good indication that 
the L.H. surge is occurring.  
Negative for L.H. surge  
If two bands are visible but the test band is of a less intense colour (paler) than the control 
band or cannot be seen, this means the L.H. level is at or near its normal level and that the 
surge is not in progress. You should continue with daily testing.  
Invalid result       
If no control band appears within 5 minutes, the result is invalid and should be ignored. A 
visible control line is needed in all cases to confirm a proper test result. Repeat test with a 
new test kit.  
 
g. Log booklet non-oc users 
 
Daily logging booklet  
 
For every day in the monitoring months complete: 
• Menstrual day tracker  
• Log your basal body temperature 
• Physical activity level  
 
Urine dip-stick: 
• Cycle1: Please start this from day ____ and continue daily for 10 days 




• Cycle 3: Please start this from day _____ and continue daily for 10 days 
 
Instructions for basal body temperature: 
• Record the temperature every morning before getting out of bed without sitting up.  
• Ensure you take the reading at the same time every day 
• Follow the directions for your thermometer to get the best results  
• Record your temperature in the logbook 
 
Instructions for urine dip-stick: 
• Collect urine sample in a clean and dry container. 
• To begin testing, open the sealed pouch and remove the strip. Do not remove the strip 
until you are ready to begin testing. 
• With the arrows pointing downwards towards the urine, place the test strip vertically 
(straight) into the urine sample, for at least 10 seconds. DO NOT allow the urine to go 
above the MARK level line. 
• Remove the strip from the urine and place on a clean, dry surface. 
• Wait for coloured bands to appear. Depending on the concentration of LH in the urine 
specimen, positive results may be observed within 1 minute. However, to confirm 
negative results, the complete reaction time of 10 minutes is required. Results 
obtained after 30 minutes may be considered invalid.  
• Please see full information on instruction leaflet for detailed instructions, and make 
sure you are familiar with this before testing.  
  
 
Tracking of menstrual cycle  
For each month below, place a ‘S’ or ‘F’ on the date you start (S) and finish (F) your period 
 




• If your period starts before 12:00 midday, that is the day your period has started. 
• If your period starts after 12:00 midday, the following day is classified as the first day 
of your period.  
 
The last day of your period – determined by midday.  
• If your period ends before 12:00 midday, that is the day your period has finished 
• If your period ends after 12:00 midday, the following day is classified as the last day 
of your period 
 
Please also indicate the urine dipstick results (positive or negative) for relevant days, in the 
lower row of each section (see template 1)  
 
Summary: 
• S – started period     Positive = dipstick positive result (i.e., 2 lines) 
• F – finished period     Negative = dipstick negative result (i.e., 1 line, 
or 2nd line very light) 
 
Tracking of physical activity:  
Please provide brief details of your current weekly levels of physical activity (sport, physical 
fitness or conditioning activities), using the following classification for exertion level: 
 
L    = light (slightly breathless) 
M  = moderate (breathless) 
V   = vigorous (very breathless) 
Template two: example of tracking physical activity
Day & Date: Activity Duration (mins) Level 
Monday 13/07 Spin 45 V 
Tuesday 14/07     
Wednesday 15/07 Yoga 30 L 
Thursday 16/07 5 km run 32 min M 
Friday 17/07    
Saturday 18/07    





Template one: example of completed tracking log 
 
 Days in the month 
 Month  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
Period  July     S       F                    





            Neg Neg Neg Neg Neg Neg Post Pos Neg          
 Days in the month 
 Mont
h  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
Period                                  
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Physical activity log 
Day & date Activity Duration (mins) Level  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    





h. Log booklet oc users  
Daily logging booklet  
 
For every day in the monitoring months complete: 
• Menstrual day tracker  
• Log your basal body temperature 
• Log your physical activity  
 
Instructions for basal body temperature: 
• Record the temperature every morning before getting out of bed without sitting up.  
• Ensure you take the reading at the same time every day 
• Follow the directions for your thermometer to get the best results  
• Record your temperature in the logbook 
 
Questionnaires: 
• MDQ – print out  
o Complete during withdrawal phase (7 days) 
• BRUMS & Motivation  
o Pill consumption phase:  
§ day 8  
§ day 9  
§ day 10  
o Pill withdrawal phase: 
§ day 5 / 26 (post pill)  
§ day 6 / 27 (post pill) 










Tracking of menstrual cycle  
For each month below, place a ‘S’ or ‘F’ on the date you start (S) and finish (F) your period 
The first day of your period – determined by midday (spotting does not count).  
• If your period starts before 12:00 midday, that is the day your period has started. 
• If your period starts after 12:00 midday, the following day is classified as the first day 
of your period.  
The last day of your period – determined by midday.  
• If your period ends before 12:00 midday, that is the day your period has finished 
• If your period ends after 12:00 midday, the following day is classified as the last day 
of your period 
Place a ‘X’ on the date you stop taking your oral contraceptive and a ‘O’ on the day you 
start taking your oral contraceptive.  
 
Summary: 
• S – started period  
• F – finished period  
• X – date stop taking oral contraceptive  
• O – date you start taking oral contraceptive  
 
Physical activity:  
 
Please provide brief details of your current weekly levels of physical activity (sport, 
physical fitness or conditioning activities), using the following classification for 
exertion level: 
 
L    = light (slightly breathless) 
M  = moderate (breathless) 
V   = vigorous (very breathless) 
 
 
Template two: example of tracking activity 
 
 
Day & Date: Activity Duration (mins) Level 
Monday 13/07 Spin 45 V 
Tuesday 14/07     
Wednesday 15/07 Yoga 30 L 
Thursday 16/07 5 km run 32 min M 
Friday 17/07    
Saturday 18/07    
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